

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Development and validation of the health behavioural intention among at-risk smokers to prevent nasopharyngeal cancer in Sarawak, Malaysia based on the Health Belief Model

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-057552
Article Type:	Original research
Date Submitted by the Author:	29-Sep-2021
Complete List of Authors:	Kueh, Martin; RCSI & UCD Malaysia Campus, Department of Public Health Medicine Rahim, Fairuz Fadzilah; RCSI & UCD Malaysia Campus, Department of Public Health Medicine Rashid, Abdul; RCSI & UCD Malaysia Campus, Public Health Medicine
Keywords:	PUBLIC HEALTH, Head & neck tumours < ONCOLOGY, Epidemiology < ONCOLOGY

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

## Development and validation of the health behavioural intention among at-risk smokers to prevent nasopharyngeal cancer in Sarawak, Malaysia based on the Health Belief Model

Martin Kueh<sup>1</sup>, Fairuz Fadzilah Rahim<sup>1</sup> & Abdul Rashid<sup>1</sup>

<sup>1</sup>Department of Public Health Medicine, RCSI & UCD Malaysia Campus, No.4, Jalan Sepoy Lines, 10450 George Town, Penang Malaysia

Correspondence: Martin Kueh, Department of Public Health Medicine, RCSI & UCD Malaysia Campus, No.4, Jalan Sepoy Lines, 10450 George Town, Penang Malaysia. Tel: 6016-879 2269. Email: [martin1kueh@hotmail.com](mailto:martin1kueh@hotmail.com)

### Abstract

**Objective** Since lifestyle-induced NPC should not be disregarded, this study serves to develop and validate a questionnaire that aims to predict the health behaviour intentions of at-risk smokers in Sarawak, Malaysia using Health Belief Model (HBM) as the conceptual framework.

**Design** Prospective validation cross sectional study

**Setting** Urban and suburban areas in Sarawak, Malaysia.

**Participants** The preliminary items of the instrument were developed through a literature review. The instrument was translated into Malay version using forward-backward method before conducting content validity through a panel of 10 experts. Face validity was examined both quantitatively and qualitatively by 10 local smokers. The construct validity of the instrument was evaluated through exploratory factor analysis (EFA) and confirmatory factor analysis (CFA). A total of 100 local smokers participated in Phase 1 for EFA, while 171 local smokers participated in Phase 2 for CFA. Internal consistency was measured using Cronbach's alpha coefficients to evaluate the reliability.

**Results** In the exploratory stage, the factor loading of each item remained within the acceptable threshold. The final revised CFA yielded appropriate fit of the seven-factor model with the following model fit indexes: Chi Square: 641.705; df= 500; P< 0.001; CFI = 0.953; TLI: 0.948; RMSEA= 0.041. Satisfactory convergent validity and divergent validity were shown, with the exception of one pairwise construct. Internal reliability of these scales was above the desirable threshold, with Cronbach's alpha coefficients ranging from 0.705 to 0.864 and 0.838 to 0.889 for Phase 1 and 2, respectively.

**Conclusions** The study substantiated the instrument to be valid and reliable for predicting smokers' health behavioural intention to reduce cancer risk. The instrument is made up of 34 items, categorised into two sections, six HBM constructs and health behavioural intention. The instrument can be utilised for other smoking-related cancers in different at-risk population.

**Keywords:** tobacco smoking, cancer health promotion, nasopharyngeal cancer, health belief model, development and validation, Malaysia

## Article Summary

### Strengths and limitations of this study

1. This study established a novel instrument for assessing at-risk smokers' health behavioural intention to reduce NPC risk based on a well-known framework in a series of systematic validation stages, which potentially can be applied for other smoking-related cancers.
2. Face validity was undertaken both qualitatively and quantitatively to sufficiently reflect the demographic during the assessments of psychological constructs, and the validation was markedly aided by experts' evaluations.
3. This study was conducted in two phases, involving both urban and suburban local smokers, to examine concept validity, convergent validity, and divergent validity.
4. The study's generalizability may be limited by the smokers' cultural perspective, hence, further studies on smokers from different cultures will be needed to assess the instrument's psychometric properties.

### Introduction

According to the World Health Organization, tobacco smoking is a public health concern that accounts for over 8 million deaths per year and is the leading avoidable cause of illness, disability, and death globally [1]. Annually, the exposure to smoking is associated with 2.4 million deaths from cancer throughout the world [2]. The Surgeon General's report on the relationship between smoking and cancer was a watershed moment in public health towards tobacco's adverse effects on human health, followed by subsequent discovery that tobacco smoke comprises approximately 7,000 compounds, 72 of which have been identified as carcinogenic [3, 4]. Tobacco use is now causally associated to at least 20 cancer types, which also appears to have a wide-ranging immediate and long-term health benefits accompany cessation [2]. However, the harmful consequences of tobacco smoking are widely neglected or underestimated, despite the fact that it remains a significant public health hazard with the impoverished, and marginalised, as well as those in developing nations, bearing a disproportionate share of the burden [5].

Cancer is a leading cause of death as well as a major obstacle to improving lifespan in every country [6]. There is an approximately 1% reduction in overall cancer mortality rate across both sexes in both high- and low-income countries [7]. However, this is mainly a result of positive trends in the most common cancers. It fails to account for variations in the frequency and distribution of etiologic aspects such as socioeconomic, geographical, genetic, biological, ethnic, social, physical factors, as well as disparities across cancer types [7, 8]. For instance, nasopharyngeal cancer (NPC) is uncommon but unique among head and neck cancers and is a cancer disparity with its own distinct epidemiological & risk factor profiles. To reinforce the claim, the Global data from the World Health Organization illustrates poorer outcomes of NPC in endemic areas like Southeast Asia with an unbalanced global burden of 67% [9].

In Malaysia, NPC is a nationwide public health concern and the 5th most leading form of cancer, amounted to 4,597 new diagnoses of NPC for the 2012-2016 periods. The recent report from the Malaysian National Cancer Registry reports that the lifetime risk of developing NPC among men and women are 1 in 175 and 1 in 482, respectively [10]. Strikingly, there is a substantial geographical variance across the country, with Sarawak exhibiting a higher prevalence rate of NPC. A previous study

1  
2  
3 has shown a significant high age-standardised rates in males (13.5/100,000, 95% Confidence Interval  
4 = 12.2 – 15.0) and females (6.2/100,000, 95% CI= 5.7-6.7) by which the local at-risk ethnic groups  
5 including Bidayuh, Chinese, Iban, Malays and Melanau were collectively ranked top globally. In  
6 particular, the risk among the Bidayuh ethnic population, which is a native indigenous group, exceeds  
7 the general population of males and females in Sarawak by 2.3 times and 1.9 times respectively [11].  
8  
9

10 This trend was ascribed to potential risk factors, which include Epstein-Barr virus, genetic susceptibility,  
11 consumption of food with nitrous compounds and volatile nitrosamines, and complex interaction with  
12 environmental factors [12]. Among many risk factors that are associated with NPC, tobacco smoking  
13 is the most important modifiable cause of severity of NPC [13, 14]. A past study analyses 32  
14 epidemiologic studies (28 case control studies and 4 cohort studies) regarding tobacco smoking and  
15 NPC from 1979 to 2011 and reports extensively that tobacco-correlated NPC cases are 60% higher  
16 compared to non-smokers [15]. Further, National Health Morbidity Survey 2015 shows that the  
17 prevalence of tobacco smoking among the population in Sarawak is 25.4%. The native indigenous male  
18 (61.2%) and female smokers (10.7%) in Sarawak are among the highest nationwide [16]. Rahman et al  
19 indicate that an average number of tobaccos smoked is 13.6 cigarettes per day in Sarawak [17]. This  
20 lifestyle-induced NPC should not be disregarded, and it necessitates a preventative strategy centred  
21 on modifying health risk behaviours.  
22  
23  
24

25 Despite the robust establishment of cumulative impacts of tobacco smoking on the risk of cancer,  
26 there is still paucity of local studies and research effort to discover critical areas and serve as a  
27 benchmark evaluation for effectiveness of comprehensive strategies to promote cancer prevention  
28 among smokers. Therefore, given the significance of this topic, it is critical to create a questionnaire  
29 that focuses on behavioural factors and is customised to the interests of local at-risk smokers. This  
30 study serves to develop and validate a health behaviour model (HBM)-based questionnaire that aims  
31 to predict the health behaviour intentions of these smokers and their perspective and motivation  
32 towards quit smoking. A health intervention targeting NPC in this population may be more effective  
33 due to the awareness of this population regarding their increased susceptibility to NPC and may also  
34 benefit from being informed by this questionnaire.  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Conceptual Framework

The Health Belief Model (HBM) is the underpinning conceptual framework for this study to focus on psychological variables for predicting health behavioural intention. Developed in the 1950s by social psychologists at the United States Public Health Service, the Health Belief Model (HBM) is currently one of the most extensively used cognitive model and theoretical framework to help researchers understand and predict health behaviours in the population and ultimately to inform & direct health promotion and interventions [18, 19]. A large volume of past studies utilized HBM to examine health-promoting behaviours of prevention for different cancers in the context of both developed and developing countries, for example, the United States, Iran and Ethiopia [20-22]. The HBM is a value-expectancy theory, based on the hypothesis of Lewin et al that highlights the influence of two variables on behaviour: 1) the value that a person places on the outcome of the behaviour and 2) the person's perception of how likely the behaviour will lead to that outcome, in the event of illness (19). Having evolved over the past decades, HBM currently consists of 6 elements: i) perceived susceptibility, ii) perceived severity, iii) perceived benefits, iv) perceived barriers, v) cues to action, and vi) self-efficacy [23].

The first 4 refer to a person's subjective perceptions regarding 1) his/her risk of getting the disease; 2) how severe the consequences are of getting the disease; 3) the benefits from performing a health behaviour in preventing, curing, or managing the disease; and 4) obstacles to that health behaviour, e.g. financial and time costs, side effects, and so on (23). "Cue to action" is the stimulus, which may be internal (e.g. physical sensations) or external (e.g. friends with the disease, social media), that is required for that health behaviour to occur, and "self-efficacy" refers to the person's confidence how capable he/she is to successfully undertake that health behaviour [19, 23].

The following conceptual framework depicts the proposed causal relationship between HBM constructs and health behavioural intention (Figure 1):

---

## **Methods**

### **Study design and setting**

A cross-sectional study was conducted in Sarawak, Malaysia in two phases: Phase 1 from October 2020 to January 2021 and Phase 2 from January to April in 2021. Sarawak is the largest Malaysian state on the island of Borneo with a population of more than 2.6 million, made up of 26 different ethnic groups. Sarawak is divided into twelve divisions, each of which is further divided into districts and sub districts.

The sample population of Phase 1 was residents residing in urban and suburban areas in Miri, Sarawak. Phase 2 was mainly involved by residents residing in Bintulu, Kuala Baram (a federal constituency in Miri Division), and remote rural areas in Miri. They were mainly local employees working in the agricultural industry. Data were collected by eight trained research assistants. All research assistants were given a crash course in research aims, methodology and data collection, as well as a trial run to simulate real-world situations. Prior to distribution of questionnaires, participants were briefed regarding the objective and methodology of the study, as well as the benefits and risks. Involvement in this sample was entirely voluntary and did not pose any potential threat. Upon clarifying the study details, informed consents were obtained by eligible participants. The anonymity of the respondents' details was assured. The research assistants provided clarifications to smokers who requested assistance, and their replies were meticulously documented. The methodology of the study and data collection are recorded precisely and accurately throughout the process of the research.

The inclusion criteria were: 1) 18 years old and above, 2) smoked for at least a year, and 3) is a Sarawakian. Participants who did not consent to join, were pregnant, or smoked e-cigarettes only were excluded from this study.

### **Patient and Public Involvement**

No patient involved

### **Instrument development and validation**

The questionnaire is self-administered based on prior validated studies. Search was conducted using the National Library of Medicine (PubMed), Google Scholar and Cochrane Library databases by exploring various keywords: health belief model, nasopharyngeal cancer, cancer, smokers, smoking behaviours/habit, and questionnaire/tools/instruments. Questionnaires and prior literatures are adapted to examine primarily, and explicitly on smokers about NPC prevention using HBM. The initial questionnaire consisted of 41 items.

The questionnaire was developed in English and translated to Malay by two local fluent bilingual translators. An experienced researcher, whose mother tongue is Malay, compared the Malay version questionnaire to the English questionnaire. A 'back-translation' approach to English was taken independently by another two bilingual translators based on the Beaton-recommended guidelines [24].

To determine the content validity, 10 healthcare professionals including public health experts, hospital directors, and health officers were invited to evaluate the survey instrument. According to Lawshe's model, a questionnaire was designed and organized to assist and allow panellists to express clearly



1  
2  
3 their views on the importance of include different components in a model. Experts received  
4 attachments of the questionnaire via email, which was graded on a three-point scale: essential, useful  
5 but not essential, and not essential. Based on Lawshe's table, items with a CVR value greater than 0.62  
6 were kept for this study [25]. To minimise any ambiguity, the experts evaluated each item's accuracy,  
7 phrasing and grammar as well as their relevance to the construct. Modifications were made for  
8 subsequent analysis based on experts' comments and suggestions. Overall, 7 items were deleted, 2  
9 items were rephrased and 1 item was allocated into different construct.

12 Face validity was evaluated through a pilot study by 10 local smokers of different ethnic background,  
13 both qualitatively and quantitatively. Smokers who participated in the pilot study were exempted  
14 from the main study. The pilot study is conducted on a small-scale basis to ascertain the feasibility of  
15 the proposed larger study [26]. In the qualitative stage, minor revisions were made to better suit a  
16 linguistically and culturally diverse context. Based on local smokers' perspective, an item oriented  
17 towards a person's faith or spirituality to own health should also be included. Upon consensus from  
18 the researchers, we decided to add in one item, 'I think getting nose and throat cancer is my destiny  
19 and quitting smoking will not change it'. In the quantitative stage, a 5-point Likert scale Impact Score,  
20 ranging from 'extremely important' to 'least important', was measured. Once the smokers completed  
21 the questionnaire, the first step was to determine the 'Frequency' by counting the proportion of  
22 individuals who rated 4 or 5 on item im-portance. The second step was to determine the 'Importance'  
23 by calculating the mean importance score of each item. Finally, each item's Impact Score is computed  
24 using the following formula: Impact Score = Frequency (Proportion) x Importance [27]. If an item's  
25 Impact Score is equal to or more than 1.5, it is deemed suitable and kept for further evaluation [28].  
26 On the whole, the impact score for each item ranged from 1.7 to 4.6.

31 Subsequently, in the main study, to determine the construct validity, exploratory and confirmatory  
32 factor analysis were performed in two periods. In the first period, EFA (n = 100) was used to determine  
33 the number of latent factors or the relationships between the common factors. The model was later  
34 adjusted in the second period with CFA (n = 171) via structural equations using AMOS. CFA confirmed  
35 the overall fit of the model and indicated that the measures were in acceptable range [29]. Convergent  
36 validity and discriminant validity were also carried out in Phase 2.

#### 39 **Ethical considerations:**

40 This study was approved by RCSI & UCD Malaysia Campus (RUMC) Institutional Research and Ethics  
41 Committee (Approval no. JPEC 20 0027). The informed consent of all participants was obtained  
42 voluntarily, and the data was kept entirely confidentially.

#### 44 **Data management:**

45 The data was processed in Microsoft Excel before being analysed in SPSS 26.0 and AMOS 23.0. Socio-  
46 demographic characteristics are presented as number and percent-age distribution. Cronbach's  
47 alpha coefficients was used to determine internal consistency. Exploratory Factor Analysis (EFA) and  
48 Confirmatory Factor Analysis (CFA) were used to test the construct validity of each construct.  
49 Specifically, EFA was evaluated in Phase 1 and CFA in Phase 2. A p-value below 0.05 was deemed to  
50 be statistically significant.

53 EFA was performed in Phase 1 to reveal the fundamental structure of a large set of variables [29].  
54 The factors were extracted using principal component analysis with a varimax rotation. As for  
55 sampling adequacy and item-checking, the Kai-ser-Mayer-Olkin (KMO) > 0.6 and Bartlett's test for  
56 sphericity ( $p < 0.05$ ) were used. All loading factors below 0.3 were excluded from the constructs [30].  
57  
58  
59  
60

CFA was performed in Phase 2 to assess the data integrity and the structural model [29]. The acceptable level of standardised factor loading was set at 0.5 and above to ensure a satisfactory association between items and corresponding factors [31]. Different fit indices were utilised to estimate the model fit, for instance a comparative fit index (CFI) of > 0.90, Tucker-Lewis Index (TLI) > 0.90 and root mean square error of approximation (RMSEA) < 0.05 [32]. Additionally, convergent validity and discriminant validity were evaluated based on the composite reliability (CR) and average variance extracted (AVE).

### **Results:**

A total of 100 and 171 smokers participated in Phase 1 and Phase 2 of the study, respectively. The majority of the participants were males (Phase 1 86.0%; Phase 2 89.5%) and were in the 30-39 age group (Phase 1 40.0%; Phase 2 40.9%). A little over a third of the participants smoked for more than 10 years for both Phase 1 (37%) and Phase 2 (40.4%). In Phase 1, most of the participants were Iban (34%), followed by Malay (19%), Chinese (18%), Others (13%), Melanau (9%) and Bidayuh (7%). Most of the participants in Phase 2 were Chinese (33.9%), followed by Iban (24.6%), Malay (12.3%), Bidayuh (9.9%), Melanau (9.9%) and Others (9.4%). Details of the smokers' demographic information are presented in Table 1.

**Table 1: Demographic characteristics of participants**

	Phase 1 (n=100)		Phase 2 (n=171)	
	Number	Percentage (%)	Number	Percentage (%)
Age				
18-29	34	34.0	46	26.9
30-39	40	40.0	70	40.9
40-49	14	14.0	43	25.1
50-64	12	12.0	10	5.8
65 and above	0	0.0	2	1.2
Gender				
Male	86	86.0	153	89.5
Female	14	14.0	18	10.5
Ethnic groups				
Malay	19	19.0	21	12.3
Chinese	18	18.0	58	33.9
Bidayuh	7	7.0	17	9.9
Iban	34	34.0	42	24.6
Melanau	9	9.0	17	9.9
Others	13	13.0	16	9.4
Years of smoking				
1-5 years	32	32.0	44	25.7
6-10 years	31	31.0	58	33.9
More than 10 years	37	37.0	69	40.4

In Phase 1, Kaiser-Meyer-Olkin Measure of Sampling Adequacy was 0.697 and Barlett's test of the sphericity was significant ( $\chi^2 = 1,746$ ,  $p$ -value < 0.001). EFA was conducted to analyse the factor structure with principal component analysis with a varimax rotation. A decision was made to go for 7-factor structures since there is clarity of 7 constructs. The EFA found that 7 variables had eigenvalues larger than Kaiser's threshold of 1 and explained 63.0% of the variance when combined. Factor loadings of higher than 0.3 were found in all the items. Four items had cross loading with values greater than 0.3, which are PBar5, HBI2, HBI3 & HBI4. All items remain because the contents of the items were regarded as relevant based on the decision and judgment of the researchers. Table 2 shows the EFA with total items and the factor loading of each construct for the 7-factor model.

**Table 2: Result of Exploratory Factor Analysis in Phase 1 (n = 100)**

Constructs	Items	Component						
		1	2	3	4	5	6	7
Perceived Susceptibility	PSus1			0.665				
	PSus2			0.750				
	PSus3			0.810				
	PSus4			0.548				
	PSus5			0.736				
Perceived Severity	PSev1						0.558	
	PSev2						0.720	
	PSev3						0.744	
	PSev4						0.843	
	PSev5						0.730	
Perceived Benefit	PBen1	0.767						
	PBen2	0.765						
	PBen3	0.763						
	PBen4	0.792						
Perceived Barrier	PBar1					0.594		
	PBar2					0.725		
	PBar3					0.658		
	PBar4					0.709		
	PBar5					0.590		
	PBar6					0.617		
Cue to action	CUE1				0.721			
	CUE2				0.584			
	CUE3				0.736			
	CUE4				0.723			
	CUE5				0.745			
Self-efficacy	EFF1		0.721					
	EFF2		0.730					
	EFF3		0.770					
	EFF4		0.868					
	EFF5		0.625					
Health Behavioural	HBI1							0.681
	HBI2							0.307

Intention	HBI3 HBI4							0.733 0.596
Rotation Sums of Squared Loading								
Total		3.469	3.371	3.246	3.072	3.071	3.012	2.185
Percentage of Variance		10.203	9.913	9.548	9.034	9.032	8.859	6.425
Cumulative percentage		10.203	20.116	29.664	38.698	47.730	56.588	63.014

CFA was performed in Phase 2 to assess whether the seven-factor model indicated by the EFA could sufficiently represent the data. The items in their respective constructs were loaded between 0.586 and 0.898 (Table 3). For the model's fitness to increase, items with less than 0.6 and a MI more than 10 should be eliminated. Despite this, they were kept owing to the essential for the conceptual framework. Before arriving at the final model, 6 pairs of correlated errors were added to improve robustness. The resulting model is suitable for testing, as evidenced by the following model fit indexes: Chi Square: 641.705; df= 500; P< 0.001; CFI = 0.953; TLI: 0.948; RMSEA= 0.041 (90% CI 0.031 to 0.050).

**Table 3: Result of Confirmatory Factor Analysis in Phase 2 (n = 171)**

Constructs	Items	Factor Loadings	AVE	CR
Perceived Susceptibility	PSus1	0.898	0.577	0.871
	PSus2	0.819		
	PSus3	0.739		
	PSus4	0.685		
	PSus5	0.683		
Perceived Severity	PSev1	0.680	0.597	0.881
	PSev2	0.675		
	PSev3	0.806		
	PSev4	0.867		
	PSev5	0.766		
Perceived Benefit	PBen1	0.752	0.603	0.858
	PBen2	0.812		
	PBen3	0.740		
	PBen4	0.733		
Perceived Barrier	PBar1	0.586	0.572	0.888

	PBar2	0.670		
	PBar3	0.626		
	PBar4	0.886		
	PBar5	0.878		
	PBar6	0.770		
Cue to action	CUE1	0.646	0.512	0.839
	CUE2	0.721		
	CUE3	0.727		
	CUE4	0.767		
	CUE5	0.723		
Self-efficacy	EFF1	0.645	0.574	0.869
	EFF2	0.694		
	EFF3	0.827		
	EFF4	0.859		
	EFF5	0.744		
Health Behavioural Intention	HBI1	0.654	0.617	0.864
	HBI2	0.836		
	HBI3	0.867		
	HBI4	0.773		

The AVE and CR values, which are listed in [Table 3](#), were obtained after the structural model's fit was investigated to check if the items were loaded up appropriately. The AVE readings were all over the cut-off value of 0.5, ranging from 0.512 to 0.617. The CR values were all over the cut-off value of 0.7, ranging from 0.839 to 0.888. All seven constructs featured sufficient convergent validity.

Discriminant validity was evaluated using Fornell-Larcker criteria by comparing the squared correlations and AVE scores for each of the pairwise constructs (33). With the exception of Perceived Benefit <—> Cue to action, all paired constructs have shown established discriminant validity ([Table 4](#)).

**Table 4: Result of Discriminant Validity in Phase 2 (n = 171)**

	Factor Correlation	Correlation Squared	Discriminant validity
Perceived Susceptibility<-->Perceived Severity	.312	0.097	Established
Perceived Susceptibility <-->Perceived Benefit	.260	0.068	Established
Perceived Susceptibility <-->Perceived Barrier	.204	0.042	Established
Perceived Susceptibility <-->Cue to Action	.172	0.030	Established
Perceived Susceptibility <-->Self-Efficacy	.236	0.056	Established
Perceived Severity <--> Perceived Benefit	.575	0.331	Established
Perceived Severity <--> Perceived Barrier	-.042	0.176	Established
Perceived Severity <--> Cue to Action	.238	0.057	Established
Perceived Severity <--> Self-Efficacy	.257	0.066	Established
Perceived Benefit <--> Perceived Barrier	-.085	0.007	Established

Perceived Benefit <--> Cue to Action	.826	0.682	Not Established
Perceived Benefit <--> Self-Efficacy	.349	0.122	Established
Perceived Barrier <--> Cue to Action	-.001	0.000	Established
Perceived Barrier <--> Self-Efficacy	-.157	0.025	Established
Cue to Action <--> Self-Efficacy	.600	0.360	Established

Internal consistency was deemed to be acceptable if the Cronbach's alpha coefficients were more than 0.7. According to reliability analyses, Cronbach  $\alpha$  of the Perceived Susceptibility, Perceived Severity, Perceived Benefits, Perceived Barriers, Cues to Action, Self-Efficacy and Health Behavioural Intention were 0.83, 0.81, 0.86, 0.80, and 0.71, respectively in Phase 1 and 0.87, 0.88, 0.86, 0.89, 0.84, 0.87 and 0.86, respectively in Phase 2 (Table 5).

**Table 5: Cronbach's alpha of constructs in Phase 1 and 2**

Constructs	Cronbach's Alpha	
	Project 1 (n=100)	Project 2 (n=171)
Perceived Susceptibility	0.83	0.87
Perceived Severity	0.81	0.88
Perceived Benefits	0.86	0.86
Perceived Barriers	0.80	0.89
Cues to Action	0.81	0.84
Self-Efficacy	0.85	0.87
Health Behavioural Intention	0.71	0.86

### **Discussion**

At the time of the research, there are no published papers based on HBM that evaluate cancer health perception among at-risk smokers. Geographic, ethnic groups, national, social, and genetic-related factors contribute to the disproportionate burden of cancer. Sarawak's population vulnerability to NPC is among the highest in the world. Although genetic predisposition may be the most important risk factor leading to higher incidence of NPC in Sarawak, individual behavioural variables are a key driver of community health that should not be underestimated [34].

A total of 34 items in the questionnaire were formulated consistent with the HBM and divided into two sections: HBM scale for smokers' perception to NPC; and health behavioural intention to quit smoking. Both sections are constructed with a 5-point Likert scale ranging from "1 = strongly disagree" to "5 = strongly agree". The first section consists of 30 items and is arranged into six subcategories, each representing the six constructs of the health belief model – perceived susceptibility (5 items), perceived seriousness (5 items), perceived benefits (4 items), perceived barriers (6 items), cues to

1  
2  
3 action (5 items), and self-efficacy (5 items). The second section includes 4 items that predict the health  
4 behavioural intention (See Table S1 and S2).  
5

6 Based on the validity and reliability tests, including face and content validity, con-struct validity, and  
7 internal consistency, the findings of the current study indicate that the questionnaire has shown  
8 promising psychometric properties. Ten experts were ad-vised on content validity, and 7 items that  
9 did not reach the threshold of CVR based on Lawshe's Table and were judged superfluous were  
10 removed [25]. Face validity was examined in a pilot study with 10 smokers who fulfilled the eligibility  
11 requirements to ensure cultural acceptance and assess relevance and readability within the local  
12 community. Given a satisfactory Impact Score of each item, there was no elimination of item in the  
13 face validity stage. In the main study, at-risk smokers from various ethnic groups participated, which  
14 was conducted in urban, suburban and rural regions of Miri (the northern region of Sarawak). The  
15 KMO test yielded a result of 0.697 (Phase 1) and 0.830 (Phase 2) while the Bartlett's test of sphericity  
16 obtained 1746.76 (Phase 1) and 3362.86 (Phase 2), both with p-value < 0.001, indicating that the  
17 sample size was adequate and the correlation between the items was sufficient for factor analysis.  
18  
19

20  
21 Construct validity primarily concerns the degree to which a concept measures what it claims to  
22 measure [35]. In parallel to a previous study [36], a number of analyses were conducted to assess the  
23 construct validity, including EFA, CFA, as well as convergent and discriminant validity. The EFA  
24 demonstrated in Phase 1 that the seven-factor structure accounted for 63.01 percent of the overall  
25 variance. The cut-off point for factor loading was fixed at 0.30. According to EFA suggestion, HB12 item  
26 (I am trying to quit smoking to prevent nose and throat cancer at this time) should be grouped  
27 together with Perceived Benefit since the factor loading (0.537) is higher than when it is grouped  
28 with Health Behavioural Intention (0.307). This item requires immediate smoking cessation, which may  
29 spark inconsistent answers as some respondents may not be prepared to quit. The Cronbach's  $\alpha$   
30 coefficient value of 'Health Behavioural Intention' construct appeared to be satisfactory (Phase 1:  
31 0.705; Phase 2: 0.861) and this item could potentially be essential in a larger scale. Thus, the  
32 researchers agreed not to delete this item.  
33  
34  
35

36 In Phase 2, CFA was performed to see if the seven-factor model derived by EFA could demystify the  
37 association among the items based on the chosen framework. The loadings of all factors were more  
38 than 0.5. The goodness of fit was demonstrated to have an acceptable fit with the data with Chi Square  
39 = 641.705; df = 500; P < 0.001; CFI = 0.953; TLI: 0.948; RMSEA= 0.041 (90% CI 0.031 to 0.050). Following  
40 CFA, convergent and discriminant validity were tested in Phase 2. The CR and AVE values for each  
41 component have to be higher than 0.7 and 0.5; respectively, which are fulfilled in our study, suggesting  
42 an acceptable convergent validity [37]. Discriminant validity was evaluated between the HBM  
43 constructs (excluding health behavioural intention construct). To establish an acceptable discriminant  
44 validity, the factors' correlation coefficients with other factors must not be greater than each factor's  
45 AVE square root [33]. Our findings demonstrated established discriminant validity for all except for  
46 Perceived Bene-fit<-->Cue to Action. The explanation for this might be that the greater the perceived  
47 benefits of quitting smoking, the more likely smokers will look for cues to participate in such health-  
48 promoting behaviour, or vice versa. Future studies could delve deeper into the strength of the  
49 correlation, particularly between Perceived Benefit and Cue to Action. In terms of reliability, each  
50 construct for both Phase 1 and 2 showed rationally acceptable Cronbach's  $\alpha$  coefficient values as all  
51 of which were higher than 0.7, which demonstrate a high internal consistency [38].  
52  
53  
54  
55

56 This study is not free of limitations. Firstly, it is a cross-sectional study using convenience sampling,  
57 and thus, it is susceptible to recall and selection bias. Participants, on the other hand, were given  
58 ample time to consider their responses before answering the questions. The second limitation was  
59 the relatively small sample size for both EFA (n=100) and CFA (n=171). However, Kline (1994) indicated  
60

1  
2  
3 that for EFA, a sample size of 100 is sufficient, while Anderson & Gerbing (1988) suggested that  
4 CFA/SEM may be reliably examined with a minimum sample size of 100–150 [39, 40]. Finally, the  
5 smokers' cultural perspective may be represented in this study. As a result, further studies on smokers  
6 from other cultural backgrounds will be required to review the psycho-metric properties of the  
7 instrument.  
8  
9

## 10 **Conclusions**

11  
12 The current study developed a comprehensive HBM-based questionnaire with satisfactory  
13 psychometric properties, confirming the validity and reliability. Considering the complex nature of  
14 smoking habit, a study with a conceptual framework could comprehensively elucidate the predictive  
15 elements and aid us in clearer grasp of this habit, ultimately optimising health promotion [41]. Thus,  
16 this questionnaire is developed with the potential of identifying the major obstacles and facilitators  
17 to a behaviour change, which can be utilised to inform and design health interventions to im-prove  
18 their uptake and efficacy in this population that is at high risk of NPC. With the possibility of being  
19 expanded to general health campaigns that target tobacco smoking, the authors also propose further  
20 studies to use the instruments for application in other smoking-related cancers in different susceptible  
21 populations and geographic locations.  
22  
23  
24  
25

## 26 **Funding**

27  
28 There was no particular grant for this research from any funding source in the public, private, or non-  
29 profit sectors.  
30  
31  
32

## 33 **Conflicts of Interest**

34  
35 The authors declare that there are no competing or potential conflicts of interest.  
36  
37  
38

## 39 **Author Contributions**

40 Conceptualization: Kueh Martin, Fairuz Fadzilah Rahim.

41 Formal analysis: Kueh Martin, Fairuz Fadzilah Rahim.

42 Investigation: Kueh Martin, Fairuz Fadzilah Rahim.

43 Methodology: Kueh Martin, Fairuz Fadzilah Rahim.

44 Project administration: Kueh Martin, Fairuz Fadzilah Rahim.

45 Resources: Kueh Martin, Fairuz Fadzilah Rahim.

46 Software: Kueh Martin.

47 Supervision: Fairuz Fadzilah Rahim.

48 Validation: Kueh Martin.

49 Visualization: Kueh Martin.

50 Writing – original draft: Kueh Martin.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 Writing – review & editing: Kueh Martin, Fairuz Fadzilah Rahim, Abdul Rashid.  
4  
5  
6  
7  
8

### 9 **Institutional Review Board Statement**

10 The study was approved by Joint Penang Independent Ethics Committee of RCSI & UCD Malaysia  
11 Campus on 13 August 2020 (Approval no. JPEC 20 0027).  
12  
13  
14

### 15 **Informed Consent Statement**

16 Informed consent was obtained from all participants involved in the study.  
17  
18  
19  
20

### 21 **Data Availability Statement**

22 Data supporting the claimed findings can be found at  
23 [https://datadryad.org/stash/share/Qnycl5Un\\_IWTqoXOr8Zh6xJcsM0RLturj2x7qHAb-ks](https://datadryad.org/stash/share/Qnycl5Un_IWTqoXOr8Zh6xJcsM0RLturj2x7qHAb-ks).  
24  
25  
26  
27

### 28 **Acknowledgments**

29 We express our gratitude to the hospital director in Miri and local estate managers for their helpful  
30 assistance. The participants are sincerely appreciated and much acknowledged.  
31  
32  
33  
34

35 **Word count** 3934  
36  
37  
38

### 39 **References**

- 40  
41 1. Institute for Health Metrics and Evaluation (IHME). Findings from the Global Burden of  
42 Disease Study 2017. In: IHME, editor. Seattle, WA. 2018. Available from:  
43 <http://www.healthdata.org/policy-report/findings-global-burden-disease-study-2017>  
44 2. World Health Organization. WHO Report on Cancer: Setting priorities, investing wisely and  
45 providing care for all. 2020. Available from: <https://apps.who.int/iris/handle/10665/330745>  
46 3. Wellmann KF. [Smoking and Health. On the Report of the Advisory Committee to the  
47 Surgeon General of the Public Health Service]. Dtsch Med Wochenschr. 1964, 89, 1085-6.  
48 4. Hecht SS. Research opportunities related to establishing standards for tobacco products  
49 under the Family Smoking Prevention and Tobacco Control Act. Nicotine & Tobacco Research. 2011,  
50 14(1), 18-28. <https://doi.org/10.1093/ntr/ntq216>  
51 5. Viswanath K, Herbst RS, Land SR, Leischow SJ, Shields PG. Tobacco and Cancer: An American  
52 Association for Cancer Research Policy Statement. Cancer Research. 2010, 70(9), 3419-30.  
53 <https://doi.org/10.1158/0008-5472.can-10-1087>  
54 6. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer  
55 Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185  
56 Countries. CA Cancer J Clin. 2021, 71(3), 209-49. <https://doi.org/10.3322/caac.21660>  
57  
58  
59  
60

- 1  
2  
3 7. Hashim D, Boffetta P, La Vecchia C, Rota M, Bertuccio P, Malvezzi M, et al. The global  
4 decrease in cancer mortality: trends and disparities. *Ann Oncol*. 2016, 27(5), 926-33.  
5 <https://doi.org/10.1093/annonc/mdw027>
- 6  
7 8. Zavala VA, Bracci PM, Carethers JM, Carvajal-Carmona L, Coggins NB, Cruz-Correa MR, et al.  
8 Cancer health disparities in racial/ethnic minorities in the United States. *Br J Cancer*. 2021, 124(2),  
9 315-32. <https://doi.org/10.1038/s41416-020-01038-6>
- 10  
11 9. Lam KO, Lee AW, Choi CW, Sze HC, Zietman AL, Hopkins KI, et al. Global Pattern of  
12 Nasopharyngeal Cancer: Correlation of Outcome With Access to Radiation Therapy. *Int J Radiat*  
13 *Oncol Biol Phys*. 2016, 94(5), 1106-12. <https://doi.org/10.1016/j.ijrobp.2015.11.047>
- 14  
15 10. Azizah A, Hashimah B, Nirmal K, Siti Zubaidah A, Puteri N, Nabihah A, et al. Malaysian  
16 National Cancer Registry Report 2012-2016 [Internet]. Malaysia: National Cancer Institute. .  
17 Putrajaya, Malaysia: National Cancer Institute, Ministry of Health, 2019. Available from:  
18 [https://www.moh.gov.my/moh/resources/Penerbitan/Laporan/Umum/2012-  
2016%20\(MNCR\)/MNCR\\_2012-2016\\_FINAL\\_\(PUBLISHED\\_2019\).pdf](https://www.moh.gov.my/moh/resources/Penerbitan/Laporan/Umum/2012-2016%20(MNCR)/MNCR_2012-2016_FINAL_(PUBLISHED_2019).pdf)
- 19  
20 11. Devi BCR, Pisani P, Tang TS, Parkin DM. High Incidence of Nasopharyngeal Carcinoma in  
21 Native People of Sarawak, Borneo Island. *Cancer Epidemiology Biomarkers & Prevention*. 2004,  
22 13(3), 482-6.
- 23  
24 12. Tsao SW, Yip YL, Tsang CM, Pang PS, Lau VM, Zhang G, et al. Etiological factors of  
25 nasopharyngeal carcinoma. *Oral Oncol*. 2014, 50(5), 330-8.  
26 <https://doi.org/10.1016/j.oraloncology.2014.02.006>
- 27  
28 13. Linton RE, Daker M, Khoo ASB, Choo DCY, Viljoen M, Neilsen PM. Nasopharyngeal carcinoma  
29 among the Bidayuh of Sarawak, Malaysia: history and risk factors (Review). *Oncol Lett*. 2021, 22(1),  
30 514. <https://dx.doi.org/10.3892%2Fol.2021.12775>
- 31  
32 14. Guo S-S, Huang P-Y, Chen Q-Y, Liu H, Tang L-Q, Zhang L, et al. The impact of smoking on the  
33 clinical outcome of locoregionally advanced nasopharyngeal carcinoma after chemoradiotherapy.  
34 *Radiation Oncology*. 2014, 9(1), 246. <https://doi.org/10.1186/s13014-014-0246-y>
- 35  
36 15. Xue WQ, Qin HD, Ruan HL, Shugart YY, Jia WH. Quantitative association of tobacco smoking  
37 with the risk of nasopharyngeal carcinoma: a comprehensive meta-analysis of studies conducted  
38 between 1979 and 2011. *Am J Epidemiol*. 2013, 178(3), 325-38.  
39 <https://dx.doi.org/10.1093%2Faje%2Fkws479>
- 40  
41 16. Institute for Public Health. National Health and Morbidity Survey 2015 (NHMS 2015).  
42 Ministry of Health Malaysia Kuala Lumpur; 2015. Available from:  
43 <https://www.moh.gov.my/moh/resources/nhmsreport2015vol2.pdf>
- 44  
45 17. Rahman M, Arif M, Razak MFA, Suhaili M, Tambi Z, Akoi C, et al. Factors associated with  
46 tobacco use among the adult population in Sarawak, Malaysia: A cross sectional study. *Epidemiology*  
47 *Biostatistics and Public Health*. 2015, 12, 1-9. <https://doi.org/10.2427/10292>
- 48  
49 18. Champion VL, Skinner CS. The health belief model. *Health behavior and health education: Theory, research, and practice*, 4th ed. San Francisco, CA, US: Jossey-Bass, 2008. p. 45-65.
- 50  
51 19. Maiman LA, Becker MH. The Health Belief Model: Origins and Correlates in Psychological  
52 Theory. *Health Education Monographs*. 1974, 2(4), 336-53.  
53 <https://doi.org/10.1177/109019817400200404>
- 54  
55 20. Odedina FT, Dagne G, Pressey S, Odedina O, Emanuel F, Scrivens J, et al. Prostate cancer  
56 health and cultural beliefs of black men: The Florida Prostate Cancer Disparity Project. *Infectious Agents and Cancer*. 2011, 6(2), S10. <https://dx.doi.org/10.1186%2F1750-9378-6-S2-S10>
- 57  
58 21. Solomon K, Tamire M, Kaba M. Predictors of cervical cancer screening practice among HIV  
59 positive women attending adult anti-retroviral treatment clinics in Bishoftu town, Ethiopia: the  
60 application of a health belief model. *BMC Cancer*. 2019, 19(1), 989. [https://doi.org/10.1186/s12885-  
019-6171-6](https://doi.org/10.1186/s12885-019-6171-6)
- 61  
62 22. Tavafian SS, Hasani L, Aghamolaei T, Zare S, Gregory D. Prediction of breast self-examination  
63 in a sample of Iranian women: an application of the Health Belief Model. *BMC Women's Health*.  
64 2009, 9(1), 37. <https://doi.org/10.1186/1472-6874-9-37>

- 1  
2  
3 23. LaMorte., Wayne. W. The Health Belief Model: Behavioral Change Models 2019. Available  
4 from: <http://sphweb.bumc.bu.edu/otlt/MPH->  
5 [Modules/SB/BehavioralChangeTheories/BehavioralChangeTheories2.html](http://sphweb.bumc.bu.edu/otlt/MPH-Modules/SB/BehavioralChangeTheories/BehavioralChangeTheories2.html)  
6  
7 24. Beaton DE, Bombardier C, Guillemin F, Ferraz MB. Guidelines for the process of cross-  
8 cultural adaptation of self-report measures. *Spine*. 2000, 25(24), 3186-91.  
9 <https://doi.org/10.1097/00007632-200012150-00014>  
10 25. Lawshe CH. A quantitative approach to content validity. *Personnel psychology*. 1975, 28(4),  
11 563-75. <https://doi.org/10.1111/j.1744-6570.1975.tb01393.x>  
12 26. Samet JM, Wipfli H, Platz EA, Bhavsar N. A Dictionary of Epidemiology, Fifth Edition: Edited  
13 by Miquel Porta. *American Journal of Epidemiology*. 2009, 170(11), 1449-51.  
14 <https://doi.org/10.1093/aje/kwp322>  
15 27. Zamanzadeh V, Ghahramanian A, Rassouli M, Abbaszadeh A, Alavi-Majd H, Nikanfar A-R.  
16 Design and Implementation Content Validity Study: Development of an instrument for measuring  
17 Patient-Centered Communication. *J Caring Sci*. 2015, 4(2), 165-78.  
18 <https://doi.org/10.15171/jcs.2015.017>  
19 28. Lacasse Y, Godbout C, Sériès F. Health-related quality of life in obstructive sleep apnoea. *Eur*  
20 *Respir J*. 2002, 19(3), 499-503. <https://doi.org/10.1183/09031936.02.00216902>  
21 29. Suhr DD. Exploratory or confirmatory factor analysis? 2006. Available from:  
22 <https://support.sas.com/resources/papers/proceedings/proceedings/sugi31/200-31.pdf>  
23 30. Munro BH. *Statistical methods for health care research: lippincott williams & wilkins*; 2005.  
24 31. Xiang B, Wong HM, Cao W, Perfecto AP, McGrath CPJ. Development and validation of the  
25 Oral health behavior questionnaire for adolescents based on the health belief model (OHBQAIBM).  
26 *BMC Public Health*. 2020, 20(1), 701. <https://doi.org/10.1186/s12889-020-08851-x>  
27 32. Brown TA. *Confirmatory factor analysis for applied research*. New York, NY, US: The Guilford  
28 Press; 2006.  
29 33. Fornell C, Larcker DF. Evaluating structural equation models with unobservable variables and  
30 measurement error. *Journal of marketing research*. 1981, 18(1), 39-50.  
31 <https://doi.org/10.2307/3151312>  
32 34. McGinnis JM, Williams-Russo P, Knickman JR. The case for more active policy attention to  
33 health promotion. *Health affairs*. 2002, 21(2), 78-93. <https://doi.org/10.1377/hlthaff.21.2.78>  
34 35. Cohen RJ, Swerdlik ME, Phillips SM. *Psychological testing and assessment: An introduction to*  
35 *tests and measurement*: Mayfield Publishing Co; 1996.  
36 36. Shamsalinia A, Moradi M, Farahani MA, Masoudi R, Ghadimi R, Rad RE, et al. Designing and  
37 psychometric evaluation of disease-related fear scale (D-RFS) in adults with epilepsy: A sequential  
38 exploratory mixed methods design. *Epilepsy & Behavior*. 2020, 110, 107169.  
39 <https://doi.org/10.1016/j.yebeh.2020.107169>  
40 37. Schreiber JB, Nora A, Stage FK, Barlow EA, King J. Reporting structural equation modeling  
41 and confirmatory factor analysis results: A review. *The Journal of educational research*. 2006, 99(6),  
42 323-38. <https://doi.org/10.3200/JOER.99.6.323-338>  
43 38. Kline P. *The handbook of psychological testing*: Psychology Press, 2000.  
44 <https://doi.org/10.4324/9781315812274>  
45 39. Kline P. *An Easy Guide to Factor Analysis (1st ed.)*. 1st edition ed. London. 1994, p. 208.  
46 <https://doi.org/10.4324/9781315788135>  
47 40. Anderson JC, Gerbing DW. Structural Equation Modeling in Practice: A Review and  
48 Recommended Two-Step Approach. *Psychological Bulletin*. 1988, 103, 411-423.  
49 <http://dx.doi.org/10.1037/0033-2909.103.3.411>  
50 41. Reisi M, Javadzade S, Shahnazi H, Sharifirad G, Charkazi A, Moodi M. Factors affecting  
51 cigarette smoking based on health-belief model structures in pre-university students in Isfahan, Iran.  
52 *Journal of Education and Health Promotion*. 2014, 3(1), 23. [https://doi.org/10.4103/2277-](https://doi.org/10.4103/2277-9531.127614)  
53 [9531.127614](https://doi.org/10.4103/2277-9531.127614)  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **Figure**  
4

5 Figure 1. Conceptual framework of the study based on Health Belief Model  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1. Conceptual framework of the study based on Health Belief Model

144x82mm (157 x 157 DPI)

**Table S1: Questionnaire to predict health behavioural intention to prevent nasopharyngeal cancer among at-risk smoker (English Version)**

**Section 1: Perceptions towards nose and throat cancer**

Please choose the best answer options to indicate your level of agreement.

Constructs of Health Belief Model	Questions	Strongly disagree	Disagree	Neutral	Agree	Strongly agree
Perceived susceptibility	1. I feel that I will get nose and throat cancer in the future.					
	2. My chances of getting nose and throat cancer are high.					
	3. I cannot avoid myself from getting nose and throat.					
	4. I am worried about getting nose and throat.					
	5. My smoking habit makes me more likely than average to get nose and throat cancer.					
Perceived seriousness	6. The thought of nose and throat cancer scares me.					
	7. If I had nose and throat cancer, the cost of treatment can be a financial strain.					
	8. Nose and throat cancer would threaten a relationship with my family.					
	9. If I had nose and throat cancer my					

	whole life would change.					
	10. If I developed nose and throat cancer, I would not live long.					
Perceived benefits	11. Quit smoking decreases my chance of getting nose and throat cancer.					
	12. Quit smoking decreases my chance of dying from nose and throat cancer.					
	13. Quit smoking can improve my health.					
	14. I feel less anxious about nose and throat cancer if I quit smoking.					
Perceived barriers	15. It is difficult to quit tobacco smoking (e.g. peer pressure).					
	16. I feel anxious without smoking,					
	17. Tobacco smoking relieves my stress.					
	18. I experience headache without smoking.					
	19. I experience excessive salivation without smoking.					
	20. I think getting nose and throat cancer is destiny and quitting smoking will not change it.					
Cues to action	21. I will stop me from smoking if I have social support.					
	22. I will stop smoking if there are					

	information sources that reminds me. Examples of sources include: the internet, newspapers, radio and TV.					
	23. I will stop smoking if I have the will to change.					
	24. I will stop smoking if I know the diseases related to smoking.					
	25. I will stop smoking if there are health professionals to assist me.					
Self-efficacy	26. I can refuse to smoke when I am thinking about difficult problem.					
	27. I can refuse the urge to smoke.					
	28. I can refuse to smoke when I see someone else smoking.					
	29. I can refuse to smoke when offered by my friends/ family.					
	30. I can refuse from buying cigarettes when I have extra pocket money.					

**Section 2: Health Behavioural Intention to quit smoking**

Please choose the best answer options to indicate your level of agreement.

Statements	Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1. I would like to lead a healthier lifestyle to prevent nose and throat cancer.					



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

2. I am trying to quit smoking to prevent nose and throat cancer at this time.					
3. I plan to quit smoking to prevent nose and throat cancer within six months.					
4. I would like to quit smoking to prevent nose and throat cancer but have never really tried.					

For peer review only

**Table S2: Questionnaire to predict health behavioural intention to prevent nasopharyngeal cancer among at-risk smoker (Malay Version)**

**Bahagian 1: Persepsi terhadap kanser hidung dan tekak.**

Sila bulatkan dengan pilihan jawapan terbaik untuk menunjukkan tahap persetujuan anda.

Domain Model Kepercayaan Kesihatan	Soalan	Sangat tidak setuju	Tidak setuju	Kurang bersetuju	Setuju	Sangat setuju
Kepercayaan kepada tiada daya tahan	1. Saya merasakan bahawa saya akan mendapat kanser pangkal hidung pada masa akan datang.					
	2. Peluang saya mendapat kanser pangkal hidung adalah tinggi.					
	3. Saya tidak dapat mengelakkan diri daripada mendapat kanser pangkal hidung.					
	4. Saya bimbang terkena kanser pangkal hidung kerana ahli keluarga saya menghadapi masalah ini.					
	5. Tabiat merokok saya menyebabkan saya lebih berisiko menghidap kanser pangkal hidung.					
Kepercayaan kepada bahaya	6. Risiko dan kesan-kesan kanser pangkal hidung menakutkan saya.					
	7. Jika saya mempunyai kanser pangkal hidung, kos rawatan akan					

	menjadi beban kewangan keluarga saya.					
	8. Kanser pangkal hidung akan merosakkan hubungan antara ahli keluarga saya.					
	9. Jika saya mempunyai kanser pangkal hidung, kehidupan saya akan diubah.					
	10. Jika saya mempunyai kanser pangkal hidung, saya tidak akan hidup lama.					
Kepercayaan kepada manfaat	11. Berhenti merokok akan mengurangkan peluang saya mendapat kanser pangkal hidung.					
	12. Berhenti merokok akan mengurangkan risiko kematian disebabkan kanser pangkal hidung.					
	13. Berhenti merokok amat penting untuk meningkatkan kesihatan saya.					
	14. Berhenti merokok akan mengurangkan kerisauan saya terhadap kanser pangkal hidung.					
Kepercayaan kepada halangan	15. Saya berasa sukar untuk menghentikan tabiat merokok atas sebab tekanan					

	rakan sebaya dan lain-lain.					
	16. Saya akan berasa bimbang akan sesuatu tanpa merokok.					
	17. Merokok menghilangkan tekanan saya.					
	18. Jika saya tidak merokok, saya akan mengalami sakit kepala					
	19. Jika saya tidak merokok, saya akan mengalami air liur berlebihan.					
	20. Saya rasa mendapat kanser pangkal hidung adalah takdir dan berhenti merokok tidak akan mengubahnya.					
Isyarat untuk bertindak	21. Jika saya mempunyai sokongan sosial, saya akan berhenti merokok.					
	22. Jika beberapa sumber maklumat mengingatkan saya, saya akan berhenti merokok. Contoh sumber maklumat termasuk internet, surat khabar, radio dan TV.					
	23. Saya akan berhenti merokok sekiranya saya mempunyai kemahuan untuk berubah.					
	24. Menyedari bahaya merokok					

	akan membantu saya berhenti merokok.					
	25. Saya akan berhenti merokok sekiranya ahli profesional kesihatan membantu saya					
Keberkesanan diri	26. Saya boleh menolak merokok apabila saya ingin memikirkan masalah yang sukar.					
	27. Saya boleh menolak merokok apabila saya mempunyai keinginan untuk merokok.					
	28. Saya boleh menolak merokok apabila saya melihat orang lain merokok.					
	29. Saya boleh menolak merokok apabila kawan/ keluarga saya mengajak saya untuk merokok.					
	30. Saya boleh menolak membeli rokok apabila saya mempunyai lebih wang saku.					

## Bahagian 2: Tingkah laku untuk berhenti merokok demi kesihatan

Sila bulatkan dengan pilihan jawapan terbaik untuk menunjukkan tahap persetujuan anda.

Soalan	Sangat tidak bersetuju	Tidak setuju	Kurang bersetuju	Setuju	Sangat setuju
1. Saya akan menjalani gaya hidup yang lebih sihat untuk mencegah kanser pangkal hidung.					

2. Saya sedang berusaha untuk berhenti merokok untuk mengurangi risiko kanker pangkal hidung pada masa ini.					
3. Saya merancang untuk berhenti merokok untuk mengurangi risiko kanker pangkal hidung dalam masa enam bulan.					
4. Saya ingin berhenti merokok untuk mengurangi risiko kanker pangkal hidung tetapi tidak pernah mencuba.					

# Reporting checklist for cross sectional study.

Based on the STROBE cross sectional guidelines.

## Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the STROBE cross sectional reporting guidelines, and cite them as:

von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.

	Reporting Item	Page Number
<b>Title and abstract</b>		
Title	<a href="#">#1a</a> Indicate the study's design with a commonly used term in the title or the abstract	1
Abstract	<a href="#">#1b</a> Provide in the abstract an informative and balanced summary of what was done and what was found	1
<b>Introduction</b>		
Background / rationale	<a href="#">#2</a> Explain the scientific background and rationale for the investigation being reported	2-3
Objectives	<a href="#">#3</a> State specific objectives, including any prespecified hypotheses	3
<b>Methods</b>		
Study design	<a href="#">#4</a> Present key elements of study design early in the paper	5

1	Setting	<a href="#">#5</a>	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5
2				
3				
4				
5				
6	Eligibility criteria	<a href="#">#6a</a>	Give the eligibility criteria, and the sources and methods of selection of participants.	5
7				
8				
9				
10		<a href="#">#7</a>	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	4-5
11				
12				
13				
14				
15	Data sources / measurement	<a href="#">#8</a>	For each variable of interest give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group. Give information separately for for exposed and unexposed groups if applicable.	5-6
16				
17				
18				
19				
20				
21				
22				
23				
24				
25	Bias	<a href="#">#9</a>	Describe any efforts to address potential sources of bias	5 - 6. We involved experts and participants of different background and ethnic groups in hopes to reduce biasness.
26				
27				
28				
29				
30				
31				
32				
33	Study size	<a href="#">#10</a>	Explain how the study size was arrived at	12
34				
35				
36	Quantitative variables	<a href="#">#11</a>	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen, and why	6
37				
38				
39				
40				
41	Statistical methods	<a href="#">#12a</a>	Describe all statistical methods, including those used to control for confounding	6
42				
43				
44				
45	Statistical methods	<a href="#">#12b</a>	Describe any methods used to examine subgroups and interactions	6
46				
47				
48				
49	Statistical methods	<a href="#">#12c</a>	Explain how missing data were addressed	N/A. No missing data was collected.
50				
51				
52				
53	Statistical methods	<a href="#">#12d</a>	If applicable, describe analytical methods taking account of sampling strategy	6
54				
55				
56	Statistical methods	<a href="#">#12e</a>	Describe any sensitivity analyses	N/A
57				
58				
59				
60				



1 **Results**

2

3

4 Participants [#13a](#) Report numbers of individuals at each stage of N/A. Do not have a list of

5 study—eg numbers potentially eligible, examined for numbers potentially eligible.

6 eligibility, confirmed eligible, included in the study,

7 completing follow-up, and analysed. Give

8 information separately for for exposed and unexposed

9 groups if applicable.

10

11

12

13 Participants [#13b](#) Give reasons for non-participation at each stage N/A

14

15 Participants [#13c](#) Consider use of a flow diagram N/A. Do not have a list of

16 numbers potentially eligible.

17

18

19 Descriptive data [#14a](#) Give characteristics of study participants (eg 7

20 demographic, clinical, social) and information on

21 exposures and potential confounders. Give

22 information separately for exposed and unexposed

23 groups if applicable.

24

25

26

27 Descriptive data [#14b](#) Indicate number of participants with missing data for N/A. No missing data was

28 each variable of interest collected

29

30

31 Outcome data [#15](#) Report numbers of outcome events or summary N/A. This study focuses on

32 measures. Give information separately for exposed validating the questionnaire

33 and unexposed groups if applicable. with a series of analysis.

34

35

36

37 Main results [#16a](#) Give unadjusted estimates and, if applicable, N/A. This study focuses on

38 confounder-adjusted estimates and their precision (eg, validating the questionnaire

39 95% confidence interval). Make clear which with a series of analysis.

40 confounders were adjusted for and why they were

41 included

42

43

44

45 Main results [#16b](#) Report category boundaries when continuous N/A. This study focuses on

46 variables were categorized validating the questionnaire

47 with a series of analysis.

48

49

50 Main results [#16c](#) If relevant, consider translating estimates of relative N/A. This study focuses on

51 risk into absolute risk for a meaningful time period validating the questionnaire

52 with a series of analysis.

53

54

55

56 Other analyses [#17](#) Report other analyses done—e.g., analyses of 8-11

57 subgroups and interactions, and sensitivity analyses

58

59

60

## Discussion

Key results	<a href="#">#18</a>	Summarise key results with reference to study objectives	11-12
Limitations	<a href="#">#19</a>	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias.	12
Interpretation	<a href="#">#20</a>	Give a cautious overall interpretation considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence.	12
Generalisability	<a href="#">#21</a>	Discuss the generalisability (external validity) of the study results	12

## Other Information

Funding	<a href="#">#22</a>	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	13
---------	---------------------	---	----

### Notes:

- 9: 5 - 6. We involved experts and participants of different background and ethnic groups in hopes to reduce biasness.
- 12c: N/A. No missing data was collected.
- 13a: N/A. Do not have a list of numbers potentially eligible.
- 13c: N/A. Do not have a list of numbers potentially eligible.
- 14b: N/A. No missing data was collected
- 15: N/A. This study focuses on validating the questionnaire with a series of analysis.
- 16a: N/A. This study focuses on validating the questionnaire with a series of analysis.
- 16b: N/A. This study focuses on validating the questionnaire with a series of analysis.
- 16c: N/A. This study focuses on validating the questionnaire with a series of analysis. The STROBE checklist is distributed under the terms of the Creative Commons Attribution License CC-BY. This

checklist was completed on 19. September 2021 using <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

# BMJ Open

**Development and validation of the health behavioural intention on smoking cessation to prevent nasopharyngeal cancer in Sarawak, Malaysia based on the Health Belief Model: a cross-sectional study**

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-057552.R1
Article Type:	Original research
Date Submitted by the Author:	20-May-2022
Complete List of Authors:	Kueh, Martin; RCSI & UCD Malaysia Campus, Department of Public Health Medicine Rahim, Fairuz Fadzilah; RCSI & UCD Malaysia Campus, Department of Public Health Medicine Rashid, Abdul; RCSI & UCD Malaysia Campus, Public Health Medicine
<b>Primary Subject Heading</b>:	Public health
Secondary Subject Heading:	Public health, Smoking and tobacco, Oncology
Keywords:	PUBLIC HEALTH, Head & neck tumours < ONCOLOGY, Epidemiology < ONCOLOGY

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 **Development and validation of the health behavioural intention on smoking cessation to prevent**  
4 **nasopharyngeal cancer in Sarawak, Malaysia based on the Health Belief Model: a cross-sectional**  
5 **study**  
6

7 Martin Kueh<sup>1</sup>, Fairuz Fadzilah Rahim<sup>1</sup> & Abdul Rashid<sup>1</sup>  
8

9 <sup>1</sup>Department of Public Health Medicine, RCSI & UCD Malaysia Campus, No.4, Jalan Sepoy Lines, 10450  
10 George Town, Penang Malaysia  
11

12  
13 Correspondence: Martin Kueh, Department of Public Health Medicine, RCSI & UCD Malaysia Campus,  
14 No.4, Jalan Sepoy Lines, 10450 George Town, Penang Malaysia. Tel: 6016-879 2269. Email:  
15 [martin1kueh@hotmail.com](mailto:martin1kueh@hotmail.com)  
16

17  
18  
19 **Abstract**

20  
21 **Objective** Lifestyle-induced nasopharyngeal carcinoma (NPC) is a serious but preventable risk factor.  
22 This study serves to develop and validate a questionnaire that aims to predict the health behavioural  
23 intention on smoking cessation in Sarawak, Malaysia using the Health Belief Model (HBM).  
24

25 **Design** A cross-sectional study  
26

27 **Setting** Urban and suburban areas in Sarawak, Malaysia.  
28

29 **Participants** The preliminary items of the instrument were developed through a literature review. The  
30 instrument was translated into Malay language using forward-backwards method before conducting  
31 the content validity through a panel of 10 experts. Face validity was examined both quantitatively and  
32 qualitatively by 10 local smokers. The construct validity of the instrument was evaluated through  
33 exploratory factor analysis (EFA) and confirmatory factor analysis (CFA). A total of 100 local smokers  
34 participated in Phase 1 for EFA, while 171 local smokers participated in Phase 2 for CFA. Internal  
35 consistency was measured using Cronbach's alpha coefficients to evaluate the reliability.  
36  
37

38 **Results** In the exploratory stage, the factor loading of each item remained within the acceptable  
39 threshold. The final revised CFA yielded appropriate fit of the seven-factor model with the following  
40 model fit indexes: Chi-Square: 641.705; df= 500; P< 0.001; CFI = 0.953; TLI: 0.948; RMSEA= 0.041.  
41 Satisfactory convergent validity and divergent validity were shown, with the exception of one pairwise  
42 construct. The internal reliability of these scales was above the desirable threshold, with Cronbach's  
43 alpha coefficients ranging from 0.705 to 0.864 and 0.838 to 0.889 for Phase 1 and 2, respectively.  
44  
45

46 **Conclusions** The study substantiated the instrument to be valid and reliable for predicting smokers'  
47 health behavioural intention to reduce cancer risk. The instrument is made up of 34 items, categorised  
48 into two sections, six HBM constructs and health behavioural intention. The instrument can be utilised  
49 for other smoking cessation-related cancers in different at-risk population.  
50

51 **Keywords:** tobacco smoking, cancer health promotion, nasopharyngeal cancer, health belief model,  
52 development and validation, quit smoking, smoking cessation  
53  
54  
55  
56  
57  
58  
59  
60

## Article Summary

### Strengths and limitations of this study

1. This study established a novel instrument for assessing at-risk smokers' health behavioural intention to reduce NPC risk based on a well-known framework in a series of systematic validation stages, which potentially can be applied for other smoking-related cancers.
2. Face validity was undertaken both qualitatively and quantitatively to sufficiently reflect the demographic during the assessments of psychological constructs. The validation was markedly aided by experts' evaluations.
3. This study was conducted in two phases, involving both urban and suburban smokers, to examine concept validity, convergent validity, and divergent validity.
4. The study's generalizability may be limited by the smokers' cultural perspective, hence, further studies on smokers from different cultures will be needed to assess the instrument's psychometric properties.

### Introduction

According to the World Health Organization, tobacco smoking is a public health concern that accounts for over 8 million deaths per year and is the leading avoidable cause of illness, disability, and death globally [1]. Annually, exposure to smoking is associated with 2.4 million deaths from cancer throughout the world [2]. The report from the Surgeon General of the United States of America (USA) associating smoking and cancer was a watershed moment in public health towards tobacco's adverse effects on human health, followed by subsequent discovery that tobacco smoke comprises approximately 7,000 compounds, 72 of which are carcinogenic [3, 4]. Tobacco use is now causally associated with at least 20 cancer types, which also appears to have a wide-ranging immediate and long-term health benefits accompanying smoking cessation [2]. However, the harmful consequences of tobacco smoking are widely neglected or underestimated, despite the fact that it remains a significant public health hazard among with the impoverished, and marginalised, as well as those in developing nations, which bear a disproportionate share of the burden [5].

Cancer is a leading cause of death as well as a major obstacle to improving lifespan in every country [6]. There is an approximately 1% reduction in the overall cancer mortality rate across both sexes in both high- and low-income countries [7]. However, this is mainly a result of positive trends in the most common cancers. It fails to account for variations in the frequency and distribution of aetiologic aspects such as socioeconomic, geographical, genetic, biological, ethnic, social, and physical factors, as well as disparities across cancer types [7, 8]. For instance, nasopharyngeal cancer (NPC) is uncommon but unique among head and neck cancers and is a cancer disparity with its own distinct epidemiological & risk factor profiles. To reinforce the claim, the Global data from the World Health Organization illustrates poorer outcomes of NPC in endemic areas like Southeast Asia with an unbalanced global burden of 67% [9].

In Malaysia, NPC is a nationwide public health concern and the 5th leading form of cancer, amounting to 4,597 new diagnoses of NPC for the 2012-2016 period. The recent report from the Malaysian National Cancer Registry reported that the lifetime risk of developing NPC among men and women are 1 in 175 and 1 in 482, respectively [10]. Strikingly, there is a substantial geographical variance within the country, with Sarawak exhibiting a higher prevalence rate of NPC. A previous study has

1  
2  
3 shown a significant high age-standardised rates in males (13.5/100,000, 95% Confidence Interval =  
4 12.2 – 15.0) and females (6.2/100,000, 95% CI= 5.7-6.7) by which the local at-risk ethnic groups  
5 including Bidayuh, Chinese, Iban, Malays and Melanau were collectively ranked top globally. In  
6 particular, the risk among the Bidayuh ethnic population, which is a native indigenous group, exceeds  
7 the general population of males and females in Sarawak by 2.3 times and 1.9 times respectively [11].  
8  
9

10 This trend has been ascribed to potential risk factors, which include Epstein-Barr virus, genetic  
11 susceptibility, consumption of food with nitrous compounds and volatile nitrosamines, and complex  
12 interaction with environmental factors [12]. Among many risk factors that are associated with NPC,  
13 tobacco smoking is the most important modifiable cause of the severity of NPC [13, 14]. A meta-  
14 analysis 32 epidemiologic studies (28 case-control studies and 4 cohort studies) regarding tobacco  
15 smoking and NPC from 1979 to 2011 reported that tobacco-correlated NPC cases were 60% higher  
16 compared to non-smokers [15]. The Malaysian National Health and Morbidity Survey 2015 showed  
17 that the prevalence of tobacco smoking among the population in Sarawak was 25.4%. The native  
18 indigenous male (61.2%) and female smokers (10.7%) in Sarawak were among the highest nationwide  
19 [16]. Rahman et al (2015) indicated that the average number of tobaccos smoked was 13.6 cigarettes  
20 per day in Sarawak [17]. This lifestyle-induced NPC is a serious concern, and necessitates a  
21 preventative strategy centred on modifying health risk behaviours.  
22  
23  
24

25 Despite the robust establishment of cumulative impact of tobacco smoking on the risk of cancer, there  
26 is still a paucity of local studies and research efforts to discover critical areas and serve as a benchmark  
27 for the evaluation of the effectiveness of comprehensive strategies to promote cancer prevention  
28 among smokers. Hence, given the significance of this subject, it is imperative to create a questionnaire  
29 that focuses on behavioural factors and is customised to the interests of local at-risk smokers. The  
30 Health Belief Model (HBM), an approachable theoretical model that could aid in the understanding of  
31 the individual's or a smoker's belief on the health-related behavioural intention [18, 19]. This HBM  
32 can further predict the smokers' effort to improve health or their health-seeking behaviours in the  
33 preventive practices of NPC. This study serves to develop and validate a health behaviour model  
34 (HBM)-based questionnaire that aims to predict the health behavioural intention of these smokers  
35 and their perspective and motivation towards smoking cessation.  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## Conceptual Framework

The Health Belief Model (HBM) is the underpinning conceptual framework for this study to focus on psychological variables for predicting health behavioural intention. Developed in the 1950s by social psychologists at the United States Public Health Service, the Health Belief Model (HBM) is currently one of the most extensively used cognitive model and theoretical framework to help researchers understand and predict health behaviours in the population and ultimate guide for health promotion and interventions activities [18, 19]. A large volume of studies in the past utilized HBM to examine health-promoting behaviours for the prevention of different cancers in both developed and developing countries including, the USA, Iran and Ethiopia [20-22]. The HBM is a value-expectancy theory, based on the hypothesis of Lewin et al that highlights the influence of two variables on behaviour: 1) the value that a person places on the outcome of the behaviour and 2) the person's perception of how likely the behaviour will lead to that outcome, in the event of an illness (19). Having evolved over the past decades, HBM currently consists of 6 elements: i) perceived susceptibility, ii) perceived severity, iii) perceived benefits, iv) perceived barriers, v) cues to action, and vi) self-efficacy [23].

The first four refer to a person's subjective perceptions regarding 1) his/her risk of getting the disease; 2) how severe the consequences are of getting the disease; 3) the benefits from performing a health behaviour in preventing, curing, or managing the disease; and 4) obstacles to that health behaviour, e.g. financial and time costs, side effects, and so on (23). "Cue to action" is the stimulus, which may be internal (e.g., physical sensations) or external (e.g., friends with the disease, social media), that is required for that health behaviour to occur, and "self-efficacy" refers to the person's confidence on how capable he/she is to successfully undertake that health behaviour [19, 23].

---

## **Methods**

### **Study design and setting**

A cross-sectional study was conducted in Sarawak, Malaysia in two phases: Phase 1 from October 2020 to January 2021 and Phase 2 from January to April 2021. Sarawak is the largest Malaysian state on the island of Borneo with a population of more than 2.6 million, made up of 26 different ethnic groups. Sarawak is divided into twelve divisions, each of which is further divided into districts and sub-districts.

The sample population of Phase 1 were residents residing in urban and suburban areas in Miri, Sarawak. Phase 2 mainly involved by residents residing in Bintulu, Kuala Baram (a federal constituency in Miri Division), and remote rural areas in Miri. They were mainly local employees working in the agricultural industry. Data were collected by eight trained research assistants. All research assistants were given a crash course in the research aims, methodology and data collection, as well as a trial run to simulate real-world situations. Prior to the distribution of questionnaires, participants were briefed regarding the objective and methodology of the study, as well as the benefits and risks involved. Involvement in this sample was entirely voluntary and did not pose any potential threat. Upon clarifying the study details, informed consent was obtained from each participant. The anonymity of the respondents' details is assured. The research assistants provided clarifications to smokers who requested assistance. The methodology of the study and data collection were recorded precisely and accurately throughout the process of the research.

The inclusion criteria were: 1) 18 years old and above, 2) smoked for at least a year, and 3) is a Sarawakian. Participants who did not consent to participate, were pregnant, or smoked e-cigarettes only were excluded from this study.

### **Patient and Public Involvement**

No patient was involved in this study.

### **Instrument development and validation**

The questionnaire was self-administered based on prior validated studies. Search was conducted using the National Library of Medicine (PubMed), Google Scholar and Cochrane Library databases by exploring various keywords: health belief model, nasopharyngeal cancer, cancer, smokers, smoking behaviours/habit, and questionnaire/tools/instruments. Questionnaires and prior literatures were examined primarily, and explicitly on smokers around about NPC prevention using HBM. The initial questionnaire consisted of 41 items.

The questionnaire was developed in English and translated to Malay by two local fluent bilingual translators. An experienced researcher, whose mother tongue is Malay, compared the Malay version of the questionnaire to the English version. A 'back-translation' approach to English was taken independently by another two bilingual translators based on the Beaton-recommended guidelines [24].

To determine the content validity, 10 healthcare professionals including public health experts, hospital directors, and health officers were invited to evaluate the survey instrument. According to Lawshe's model, a questionnaire was designed and organized to assist and allow the panellists to express clearly

1  
2  
3 their views on the importance of including different components in a model. Experts received  
4 attachments of the questionnaire via email, which was graded on a three-point scale: essential, useful  
5 but not essential, and not essential. Based on Lawshe's table, items with a CVR value greater than 0.62  
6 were retained [25]. To minimise ambiguity, the experts evaluated each item's accuracy, phrasing and  
7 grammar as well as their relevance to the construct. Modifications were made for subsequent analysis  
8 based on the experts' comments and suggestions. Overall, 7 items were deleted, 2 items were  
9 rephrased and 1 item was allocated into a different construct.  
10  
11

12 Face validity was evaluated through a pilot study by 10 local smokers of different ethnic background,  
13 both qualitatively and quantitatively. Smokers who participated in the pilot study were exempted  
14 from the main study. The pilot study is conducted on a small-scale basis to ascertain the feasibility of  
15 the proposed larger study [26]. In the qualitative stage, cognitive interviews were conducted face-to-  
16 face individually to obtain participant's feedback on their comprehension and answers. Items which  
17 were not well understood were identified from the cognitive interview [27]. Minor revisions were  
18 made to better suit a linguistically and culturally diverse context. Based on the local smokers'  
19 perspective, an item-oriented towards a person's faith or spirituality to own health was also included.  
20 With the consensus of the researchers, an item was added, 'I think getting nose and throat cancer is  
21 my destiny and quitting smoking will not change it'. In the quantitative stage, a survey was  
22 disseminated based on a Likert scale of 1 (least importance) to 5 (extremely important) to determine  
23 the clinical impact of each item. The importance score was calculated based on "clinical impact  
24 method" in which the clinical impact of each item was determined from the proportion of participants  
25 who identified it as important. This technique was chosen for better clarity where the items were  
26 ranked according to their impact score. Mean importance score of each item was computed using the  
27 following formula: Impact Score = Frequency (Proportion) x Importance. Factors were kept if the  
28 Impact Score equal or more than 1.5. They were defined as deemed suitable and kept for further  
29 evaluation [28]. In the current study, the impact score for each item ranged from 1.7 to 4.6, therefore,  
30 no item was eliminated.  
31  
32  
33  
34  
35

36 Subsequently, in the main study, to determine the construct validity, exploratory and confirmatory  
37 factor analyses were performed in two periods. In the first period, EFA (n = 100) was used to determine  
38 the number of latent factors or the relationships between the common factors. The model was later  
39 adjusted in the second period with CFA (n = 171) via structural equations using AMOS. CFA confirmed  
40 the overall fit of the model and indicated that the measures were in the acceptable range [29].  
41 Convergent validity and discriminant validity were also carried out in Phase 2.  
42  
43

#### 44 **Final scoring of the instrument:**

45 In the main study, the total mean score for each HBM components were formulated on the five-point  
46 Likert scale options from strongly disagree to strongly agree, with scores ranging from 1 to 5 points.  
47 With the exception of 'Perceived Barriers,', which is inversely proportional, a greater score reflects a  
48 firmer desire to quit smoking.  
49  
50

#### 51 **Ethical considerations:**

52 This study was approved by RCSI & UCD Malaysia Campus (RUMC) Institutional Research and Ethics  
53 Committee (Approval no. JPEC 20 0027). The informed consent of all participants was obtained  
54 voluntarily, and the data confidentiality and storage are assured.  
55  
56

#### 57 **Data management:**

58 The data was processed in Microsoft Excel before being analysed in SPSS 26.0 and AMOS 23.0 [30].  
59 Listwise deletion approach was done for missing data of less than 2%. Socio-demographic  
60

characteristics are presented as number and percentage distribution. Cronbach's alpha coefficients was used to determine internal consistency. Exploratory Factor Analysis (EFA) and Confirmatory Factor Analysis (CFA) used to test the construct validity of each construct. Specifically, EFA was evaluated in Phase 1 and CFA in Phase 2. A p-value below 0.05 was deemed to be statistically significant.

EFA was performed in Phase 1 to reveal the fundamental structure of a large set of variables [29]. The factors were extracted using principal component analysis with a varimax rotation. As for sampling adequacy and item-checking, the Kaiser-Meyer-Olkin (KMO) > 0.6 and Bartlett's test for sphericity ( $p < 0.05$ ) were used. All loading factors below 0.3 were excluded from the constructs [31].

CFA was performed in Phase 2 to assess the data integrity and the structural model [29]. The acceptable level of standardised factor loading was set at 0.5 and above to ensure a satisfactory association between items and corresponding factors [32]. Different fit indices were utilised to estimate the model fit, for instance a comparative fit index (CFI) of > 0.90, Tucker-Lewis Index (TLI) > 0.90 and root mean square error of approximation (RMSEA) < 0.05 [33]. Additionally, convergent validity and discriminant validity were evaluated based on the composite reliability (CR) and average variance extracted (AVE). The HBM components were analysed with the minimum and maximum scores, total mean score and standard deviation (SD).

### **Results:**

A total of 100 and 171 smokers participated in Phase 1 and Phase 2 of the study, respectively. The response rate for Phase 1 was 100% (100/100), whereas Phase 2 response rate was 98.3% (171/174). Majority of the participants were males (Phase 1 86.0%; Phase 2 89.5%) and were in the 30-39 age group (Phase 1 40.0%; Phase 2 40.9%). A little over a third of the participants smoked for more than 10 years for both Phase 1 (37%) and Phase 2 (40.4%). In Phase 1, most of the participants were Iban (34%), followed by Malay (19%), Chinese (18%), Others (13%), Melanau (9%) and Bidayuh (7%). Most of the participants in Phase 2 were Chinese (33.9%), followed by Iban (24.6%), Malay (12.3%), Bidayuh (9.9%), Melanau (9.9%) and Others (9.4%). Details of the smokers' demographic information are presented in Table 1.

**Table 1: Demographic characteristics of participants**

	Phase 1 (n=100)		Phase 2 (n=171)	
	Number	Percentage (%)	Number	Percentage (%)
Age				
18-29	34	34.0	46	26.9
30-39	40	40.0	70	40.9
40-49	14	14.0	43	25.1
50-64	12	12.0	10	5.8
65 and above	0	0.0	2	1.2
Gender				
Male	86	86.0	153	89.5
Female	14	14.0	18	10.5
Ethnic groups				
Malay	19	19.0	21	12.3
Chinese	18	18.0	58	33.9
Bidayuh	7	7.0	17	9.9

Iban	34	34.0	42	24.6
Melanau	9	9.0	17	9.9
Others	13	13.0	16	9.4
Years of smoking				
1-5 years	32	32.0	44	25.7
6-10 years	31	31.0	58	33.9
More than 10 years	37	37.0	69	40.4

In Phase 1, Kaiser-Meyer-Olkin Measure of Sampling Adequacy was 0.697 and Barlett's test of the sphericity was significant ( $\chi^2 = 1,746$ ,  $p$ -value < 0.001). EFA was conducted to analyse the factor structure with principal component analysis with a varimax rotation. A decision was made to go for 7-factor structures since there is clarity of 7 constructs. The EFA found that 7 variables had eigenvalues larger than Kaiser's threshold of 1 and explained 63.0% of the variance when combined. Factor loadings of higher than 0.3 were found in all the items. Four items had cross loading with values greater than 0.3, which are PBar5, HBI2, HBI3 & HBI4. All items remained because the contents of the items were regarded as relevant based on the decision and judgment of the researchers. Table 2 shows the EFA with total items and the factor loading of each construct for the 7-factor model.

**Table 2: Result of Exploratory Factor Analysis in Phase 1 (n = 100)**

Constructs	Items	Component						
		1	2	3	4	5	6	7
Perceived Susceptibility	PSus1			0.665				
	PSus2			0.750				
	PSus3			0.810				
	PSus4			0.548				
	PSus5			0.736				
Perceived Severity	PSev1						0.558	
	PSev2						0.720	
	PSev3						0.744	
	PSev4						0.843	
	PSev5						0.730	
Perceived Benefit	PBen1	0.767						
	PBen2	0.765						
	PBen3	0.763						
	PBen4	0.792						
Perceived Barrier	PBar1					0.594		
	PBar2					0.725		
	PBar3					0.658		
	PBar4					0.709		
	PBar5					0.590		
	PBar6					0.617		
Cue to action	CUE1				0.721			
	CUE2				0.584			
	CUE3				0.736			
	CUE4				0.723			
	CUE5				0.745			

Self-efficacy	EFF1		0.721					
	EFF2		0.730					
	EFF3		0.770					
	EFF4		0.868					
	EFF5		0.625					
Health Behavioural Intention	HBI1							0.681
	HBI2							0.307
	HBI3							0.733
	HBI4							0.596
Rotation Sums of Squared Loading								
Total		3.469	3.371	3.246	3.072	3.071	3.012	2.185
Percentage of Variance		10.203	9.913	9.548	9.034	9.032	8.859	6.425
Cumulative percentage		10.203	20.116	29.664	38.698	47.730	56.588	63.014

CFA was performed in Phase 2 to assess whether the seven-factor model indicated by the EFA could sufficiently represent the data. The items in their respective constructs were loaded between 0.586 and 0.898 (Table 3). For the model's fitness to increase, items with less than 0.6 and a MI more than 10 should have been eliminated. Despite this, they were kept because they were essential for the conceptual framework. Before arriving at the final model, 6 pairs of correlated errors were added to improve robustness. The resulting model was suitable for testing, as evidenced by the following model fit indexes: Chi Square: 641.705; df= 500; P< 0.001; CFI = 0.953; TLI: 0.948; RMSEA= 0.041 (90% CI 0.031 to 0.050).

**Table 3: Result of Confirmatory Factor Analysis in Phase 2 (n = 171)**

Constructs	Items	Factor Loadings	AVE	CR
Perceived Susceptibility	PSus1	0.898	0.577	0.871
	PSus2	0.819		
	PSus3	0.739		
	PSus4	0.685		
	PSus5	0.683		
Perceived Severity	PSev1	0.680	0.597	0.881
	PSev2	0.675		
	PSev3	0.806		
	PSev4	0.867		
	PSev5	0.766		

	PBen1	0.752		
	PBen2	0.812		
	PBen3	0.740		
Perceived Benefit	PBen4	0.733	0.603	0.858
	PBar1	0.586		
	PBar2	0.670		
	PBar3	0.626		
	PBar4	0.886		
	PBar5	0.878		
Perceived Barrier	PBar6	0.770	0.572	0.888
	CUE1	0.646		
	CUE2	0.721		
	CUE3	0.727		
	CUE4	0.767		
Cue to action	CUE5	0.723	0.512	0.839
	EFF1	0.645		
	EFF2	0.694		
	EFF3	0.827		
	EFF4	0.859		
Self-efficacy	EFF5	0.744	0.574	0.869
	HBI1	0.654		
	HBI2	0.836		
	HBI3	0.867		
Health Behavioural Intention	HBI4	0.773	0.617	0.864

The AVE and CR values, which are listed in [Table 3](#), were obtained after the structural model's fit was investigated to check if the items were loaded appropriately. The AVE readings were all over the cut-off value of 0.5, ranging from 0.512 to 0.617. The CR values were all over the cut-off value of 0.7, ranging from 0.839 to 0.888. All seven constructs featured sufficient convergent validity.

Discriminant validity was evaluated using Fornell-Larcker criteria by comparing the squared correlations and AVE scores for each of the pairwise constructs [34]. With the exception of Perceived Benefit < — > Cue to action, all paired constructs have shown established discriminant validity ([Table 4](#)).

**Table 4: Result of Discriminant Validity in Phase 2 (n = 171)**

	Factor Correlation	Correlation Squared	Discriminant validity
--	--------------------	---------------------	-----------------------

Perceived Susceptibility<-->Perceived Severity	.312	0.097	Established
Perceived Susceptibility <-->Perceived Benefit	.260	0.068	Established
Perceived Susceptibility <-->Perceived Barrier	.204	0.042	Established
Perceived Susceptibility <-->Cue to Action	.172	0.030	Established
Perceived Susceptibility <-->Self-Efficacy	.236	0.056	Established
Perceived Severity <--> Perceived Benefit	.575	0.331	Established
Perceived Severity <--> Perceived Barrier	-.042	0.176	Established
Perceived Severity <--> Cue to Action	.238	0.057	Established
Perceived Severity <--> Self-Efficacy	.257	0.066	Established
Perceived Benefit <--> Perceived Barrier	-.085	0.007	Established
Perceived Benefit <--> Cue to Action	.826	0.682	Not Established
Perceived Benefit <--> Self-Efficacy	.349	0.122	Established
Perceived Barrier <--> Cue to Action	-.001	0.000	Established
Perceived Barrier <--> Self-Efficacy	-.157	0.025	Established
Cue to Action <--> Self-Efficacy	.600	0.360	Established

Internal consistency was deemed to be acceptable if the Cronbach's alpha coefficients were more than 0.7. According to reliability analyses, Cronbach  $\alpha$  of the Perceived Susceptibility, Perceived Severity, Perceived Benefits, Perceived Barriers, Cues to Action, Self-Efficacy and Health Behavioural Intention were 0.83, 0.81, 0.86, 0.80, and 0.71, respectively in Phase 1 and 0.87, 0.88, 0.86, 0.89, 0.84, 0.87 and 0.86, respectively in Phase 2.

The detailed mean and standard deviation of each HBM component and Health Behavioural Intention to the socio-demographic characteristics are displayed in [Table 5](#). The total mean score for each domain ranged from 14.03 to 21.32.

**Table 5: Result of the minimum and maximum scores, total mean score and SD in Phase 2 (n=171)**

Constructs	N	Minimum	Maximum	Mean	SD
Perceived Susceptibility	171	5	25	14.03	4.04
Perceived Severity	171	5	25	16.81	4.44
Perceived Benefits	171	7	20	16.16	2.86
Perceived Barriers	171	6	30	21.32	4.99
Cue to Action	171	9	25	19.97	3.14
Self-Efficacy	171	9	25	18.04	3.87
Health Behavioural Intention	171	5	20	15.64	3.26

## **Discussion**

At the time of when the study was conducted, there were no published papers based on HBM to evaluate cancer health perception among at-risk smokers. Geographics, ethnic groups, national, social,



1  
2  
3 and genetic-related factors contribute to the disproportionate burden of cancer. Sarawak's population  
4 vulnerability to NPC is among the highest in the world. Although genetic predisposition may be the  
5 most important risk factor leading to higher incidence of NPC in Sarawak, individual behavioural  
6 variables are a key driver of community health that must not be underestimated [35].  
7

8  
9 A total of 34 items in the questionnaire were formulated consistent with the HBM and divided into  
10 two sections: HBM scale for smokers' perception to NPC; and health behavioural intention to smoking  
11 cessation. Both sections are constructed with a 5-point Likert scale ranging from "1 = strongly disagree"  
12 to "5 = strongly agree". The first section consists of 30 items and is arranged into six subcategories,  
13 each representing the six constructs of the health belief model – perceived susceptibility (5 items),  
14 perceived seriousness (5 items), perceived benefits (4 items), perceived barriers (6 items), cues to  
15 action (5 items), and self-efficacy (5 items). The second section includes 4 items that predict the health  
16 behavioural intention (See Table S1 and S2).  
17

18  
19 Based on the validity and reliability tests, including face and content validity, con-struct validity, and  
20 internal consistency, the findings of the current study indicate that the questionnaire has promising  
21 psychometric properties. Ten experts were advised on content validity, and 7 items that did not reach  
22 the threshold of CVR based on Lawshe's Table and were judged superfluous were removed [25]. Face  
23 validity was examined in a pilot study with 10 smokers who fulfilled the eligibility requirements to  
24 ensure cultural acceptance and assess relevance and readability within the local community. Given a  
25 satisfactory Impact Score of each item, there was no elimination of item in the face validity stage. In  
26 the main study, at-risk smokers from various ethnic groups participated, which was conducted in  
27 urban, suburban and rural regions of Miri (the northern region of Sarawak). The KMO test yielded a  
28 result of 0.697 (Phase 1) and 0.830 (Phase 2) while the Bartlett's test of sphericity obtained 1746.76  
29 (Phase 1) and 3362.86 (Phase 2), both with p-value < 0.001, indicating that the sample size was  
30 adequate and the correlation between the items was sufficient for factor analysis.  
31

32  
33 Construct validity primarily concerns the degree to which a concept measures what it claims to  
34 measure [36]. Similar to a previous study [37], a number of analyses were conducted to assess the  
35 construct validity, including EFA, CFA, as well as convergent and discriminant validity. The EFA  
36 demonstrated in Phase 1 that the seven-factor structure accounted for 63.01 percent of the overall  
37 variance. The cut-off point for factor loading was fixed at 0.30. According to EFA suggestion, HB12 item  
38 (I am trying to quit smoking to prevent nose and throat cancer at this time) should be grouped  
39 together with Perceived Benefit since the factor loading (0.537) is higher than when it is grouped with  
40 Health Behavioural Intention (0.307). This item requires immediate smoking cessation, which may  
41 spark inconsistent answers as some respondents may not be prepared to quit. The Cronbach's  $\alpha$   
42 coefficient value of 'Health Behavioural Intention' construct appeared to be satisfactory (Phase 1:  
43 0.705; Phase 2: 0.861) and this item could potentially be essential in a larger scale. Thus, the  
44 researchers agreed not to delete this item.  
45

46  
47 In Phase 2, CFA was performed to see if the seven-factor model derived by EFA could demystify the  
48 association among the items based on the chosen framework. The loadings of all factors were more  
49 than 0.5. The goodness of fit was demonstrated to have an acceptable fit with the data with Chi Square  
50 = 641.705; df = 500; P < 0.001; CFI = 0.953; TLI: 0.948; RMSEA = 0.041 (90% CI 0.031 to 0.050). Following  
51 CFA, convergent and discriminant validity were tested in Phase 2. The CR and AVE values for each  
52 component have to be higher than 0.7 and 0.5; respectively, which are fulfilled in the current study,  
53 suggesting an acceptable convergent validity [38]. Discriminant validity was evaluated between the  
54 HBM constructs (excluding health behavioural intention construct). To establish an acceptable  
55 discriminant validity, the factors' correlation coefficients with other factors must not be greater than  
56 each factor's AVE square root [34]. The current findings demonstrated established discriminant  
57  
58  
59  
60

1  
2  
3 validity for all except for Perceived Benefit <--> Cue to Action. The explanation for this might be that  
4 the greater the perceived benefits of quitting smoking, the more likely smokers will look for cues to  
5 participate in such health-promoting behaviour, or vice versa. Future studies could delve deeper into  
6 the strength of the correlation, particularly between Perceived Benefit and Cue to Action. In terms of  
7 reliability, each construct for both Phase 1 and 2 showed rationally acceptable Cronbach's  $\alpha$   
8 coefficient values as all of which were higher than 0.7, which demonstrates a high internal consistency  
9 [39].  
10  
11

12 This study has several limitations. Firstly, it is a cross-sectional study using convenience sampling, and  
13 thus, it is susceptible to recall and selection bias. Participants, on the other hand, were given ample  
14 time to consider their responses before answering the questions. The second limitation was the  
15 relatively small sample size for both EFA (n=100) and CFA (n=171). However, Kline (1994) indicated  
16 that for EFA, a sample size of 100 is sufficient, while Anderson & Gerbing (1988) suggested that  
17 CFA/SEM may be reliably examined with a minimum sample size of 100–150 [40, 41]. The third  
18 limitation is the health behavioural intentions investigated in this study were mainly on smoking  
19 cessation, the smokers' cultural perspective of other health behavioural intentions was not presented.  
20 Future studies looking at different perspective of health behavioural intentions will help to review the  
21 psychometric properties of the instrument.  
22  
23  
24

25 This study provides practical implications. With it being valid and reliable, the public health officials  
26 and researchers, now have a reason to launch larger population-based study on health behavioural  
27 intention to minimise NPC. Given that the current smoking rates in Malaysia remain high, this  
28 questionnaire can help in the understanding and determining the construct that influences smokers'  
29 health decisions. Subsequently, cancer risk can be reduced by better prediction, a comprehensive  
30 tobacco control programme, policy creation, and health interventions.  
31  
32

### 33 **Conclusions**

34 The current study developed a comprehensive HBM-based questionnaire with satisfactory  
35 psychometric properties, confirming the validity and reliability. A health intervention targeting NPC in  
36 this population may be more effective due to the awareness of this population regarding their  
37 increased susceptibility to NPC and may also benefit from being informed by this questionnaire. With  
38 the possibility of being expanded to general health campaigns that target tobacco smoking, the  
39 authors also propose further studies to use the instruments for application in other smoking-related  
40 cancers in different susceptible populations and geographic locations.  
41  
42  
43  
44  
45

### 46 **Funding**

47 Funding for the publication fee was received from RCSI & UCD Malaysia Campus.  
48  
49

### 51 **Conflicts of Interest**

52 The authors declare that there are no competing or potential conflicts of interest.  
53  
54  
55

### 57 **Author Contributions**

58 Conceptualization: Kueh Martin, Fairuz Fadzilah Rahim, Abdul Rashid.  
59  
60

1  
2  
3 Formal analysis: Kueh Martin, Fairuz Fadzilah Rahim.

4  
5 Investigation: Kueh Martin, Fairuz Fadzilah Rahim.

6  
7 Methodology: Kueh Martin, Fairuz Fadzilah Rahim.

8  
9 Project administration: Kueh Martin, Fairuz Fadzilah Rahim.

10  
11 Resources: Kueh Martin, Fairuz Fadzilah Rahim.

12  
13 Software: Kueh Martin.

14  
15 Supervision: Fairuz Fadzilah Rahim, Abdul Rashid.

16  
17 Validation: Kueh Martin.

18  
19 Visualization: Kueh Martin.

20  
21 Writing – original draft: Kueh Martin.

22  
23 Writing – review & editing: Kueh Martin, Fairuz Fadzilah Rahim, Abdul Rashid.

#### 24 25 26 27 **Institutional Review Board Statement**

28  
29 The study was approved by Joint Penang Independent Ethics Committee of RCSI & UCD Malaysia  
30 Campus on 13 August 2020 (Approval no. JPEC 20 0027).

#### 31 32 33 34 **Informed Consent Statement**

35  
36 Informed consent was obtained from all participants involved in the study.

#### 37 38 39 40 **Data Availability Statement**

41  
42 Data supporting the claimed findings can be found at  
43 [https://datadryad.org/stash/share/Qnycl5Un\\_IWTqoXOr8Zh6xJcsM0RLturj2x7qHAb-ks](https://datadryad.org/stash/share/Qnycl5Un_IWTqoXOr8Zh6xJcsM0RLturj2x7qHAb-ks) [30].  
44  
45

#### 46 47 **Acknowledgments**

48  
49 We express our gratitude to the hospital director in Miri and local estate managers for their helpful  
50 assistance. The participants are sincerely appreciated and much acknowledged.

51  
52  
53 **Word count** 4292

#### 54 55 56 57 **References**

1. Institute for Health Metrics and Evaluation (IHME). Findings from the Global Burden of Disease Study 2017. In: IHME, editor. Seattle, WA. 2018. Available from: <http://www.healthdata.org/policy-report/findings-global-burden-disease-study-2017>
2. World Health Organization. WHO Report on Cancer: Setting priorities, investing wisely and providing care for all. 2020. Available from: <https://apps.who.int/iris/handle/10665/330745>
3. Wellmann KF. [Smoking and Health. On the Report of the Advisory Committee to the Surgeon General of the Public Health Service]. *Dtsch Med Wochenschr.* 1964, 89, 1085-6.
4. Hecht SS. Research opportunities related to establishing standards for tobacco products under the Family Smoking Prevention and Tobacco Control Act. *Nicotine & Tobacco Research.* 2011, 14(1), 18-28. <https://doi.org/10.1093/ntr/ntq216>
5. Viswanath K, Herbst RS, Land SR, Leischow SJ, Shields PG. Tobacco and Cancer: An American Association for Cancer Research Policy Statement. *Cancer Research.* 2010, 70(9), 3419-30. <https://doi.org/10.1158/0008-5472.can-10-1087>
6. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin.* 2021, 71(3), 209-49. <https://doi.org/10.3322/caac.21660>
7. Hashim D, Boffetta P, La Vecchia C, Rota M, Bertuccio P, Malvezzi M, et al. The global decrease in cancer mortality: trends and disparities. *Ann Oncol.* 2016, 27(5), 926-33. <https://doi.org/10.1093/annonc/mdw027>
8. Zavala VA, Bracci PM, Carethers JM, Carvajal-Carmona L, Coggins NB, Cruz-Correa MR, et al. Cancer health disparities in racial/ethnic minorities in the United States. *Br J Cancer.* 2021, 124(2), 315-32. <https://doi.org/10.1038/s41416-020-01038-6>
9. Lam KO, Lee AW, Choi CW, Sze HC, Zietman AL, Hopkins KI, et al. Global Pattern of Nasopharyngeal Cancer: Correlation of Outcome With Access to Radiation Therapy. *Int J Radiat Oncol Biol Phys.* 2016, 94(5), 1106-12. <https://doi.org/10.1016/j.ijrobp.2015.11.047>
10. Azizah A, Hashimah B, Nirmal K, Siti Zubaidah A, Puteri N, Nabihah A, et al. Malaysian National Cancer Registry Report 2012-2016 [Internet]. Malaysia: National Cancer Institute. . Putrajaya, Malaysia: National Cancer Institute, Ministry of Health, 2019. Available from: [https://www.moh.gov.my/moh/resources/Penerbitan/Laporan/Umum/2012-2016%20\(MNCRR\)/MNCR\\_2012-2016\\_FINAL\\_\(PUBLISHED\\_2019\).pdf](https://www.moh.gov.my/moh/resources/Penerbitan/Laporan/Umum/2012-2016%20(MNCRR)/MNCR_2012-2016_FINAL_(PUBLISHED_2019).pdf)
11. Devi BCR, Pisani P, Tang TS, Parkin DM. High Incidence of Nasopharyngeal Carcinoma in Native People of Sarawak, Borneo Island. *Cancer Epidemiology Biomarkers & Prevention.* 2004, 13(3), 482-6.
12. Tsao SW, Yip YL, Tsang CM, Pang PS, Lau VM, Zhang G, et al. Etiological factors of nasopharyngeal carcinoma. *Oral Oncol.* 2014, 50(5), 330-8. <https://doi.org/10.1016/j.oraloncology.2014.02.006>
13. Linton RE, Daker M, Khoo ASB, Choo DCY, Viljoen M, Neilsen PM. Nasopharyngeal carcinoma among the Bidayuh of Sarawak, Malaysia: history and risk factors (Review). *Oncol Lett.* 2021, 22(1), 514. <https://dx.doi.org/10.3892%2Fol.2021.12775>
14. Guo S-S, Huang P-Y, Chen Q-Y, Liu H, Tang L-Q, Zhang L, et al. The impact of smoking on the clinical outcome of locoregionally advanced nasopharyngeal carcinoma after chemoradiotherapy. *Radiation Oncology.* 2014, 9(1), 246. <https://doi.org/10.1186/s13014-014-0246-y>
15. Xue WQ, Qin HD, Ruan HL, Shugart YY, Jia WH. Quantitative association of tobacco smoking with the risk of nasopharyngeal carcinoma: a comprehensive meta-analysis of studies conducted between 1979 and 2011. *Am J Epidemiol.* 2013, 178(3), 325-38. <https://dx.doi.org/10.1093%2Faje%2Fkws479>
16. Institute for Public Health. National Health and Morbidity Survey 2015 (NHMS 2015). Ministry of Health Malaysia Kuala Lumpur; 2015. Available from: <https://www.moh.gov.my/moh/resources/nhmsreport2015vol2.pdf>

17. Rahman M, Arif M, Razak MFA, Suhaili M, Tambi Z, Akoi C, et al. Factors associated with tobacco use among the adult population in Sarawak, Malaysia: A cross sectional study. *Epidemiology Biostatistics and Public Health*. 2015, 12, 1-9. <https://doi.org/10.2427/10292>
18. Champion VL, Skinner CS. The health belief model. *Health behavior and health education: Theory, research, and practice*, 4th ed. San Francisco, CA, US: Jossey-Bass, 2008. p. 45-65.
19. Maiman LA, Becker MH. The Health Belief Model: Origins and Correlates in Psychological Theory. *Health Education Monographs*. 1974, 2(4), 336-53. <https://doi.org/10.1177/109019817400200404>
20. Odedina FT, Dagne G, Pressey S, Odedina O, Emanuel F, Scrivens J, et al. Prostate cancer health and cultural beliefs of black men: The Florida Prostate Cancer Disparity Project. *Infectious Agents and Cancer*. 2011, 6(2), S10. <https://dx.doi.org/10.1186%2F1750-9378-6-S2-S10>
21. Solomon K, Tamire M, Kaba M. Predictors of cervical cancer screening practice among HIV positive women attending adult anti-retroviral treatment clinics in Bishoftu town, Ethiopia: the application of a health belief model. *BMC Cancer*. 2019, 19(1), 989. <https://doi.org/10.1186/s12885-019-6171-6>
22. Tavafian SS, Hasani L, Aghamolaei T, Zare S, Gregory D. Prediction of breast self-examination in a sample of Iranian women: an application of the Health Belief Model. *BMC Women's Health*. 2009, 9(1), 37. <https://doi.org/10.1186/1472-6874-9-37>
23. LaMorte., Wayne. W. The Health Belief Model: Behavioral Change Models 2019. Available from: <http://sphweb.bumc.bu.edu/otlt/MPH-Modules/SB/BehavioralChangeTheories/BehavioralChangeTheories2.html>
24. Beaton DE, Bombardier C, Guillemin F, Ferraz MB. Guidelines for the process of cross-cultural adaptation of self-report measures. *Spine*. 2000, 25(24), 3186-91. <https://doi.org/10.1097/00007632-200012150-00014>
25. Lawshe CH. A quantitative approach to content validity. *Personnel psychology*. 1975, 28(4), 563-75. <https://doi.org/10.1111/j.1744-6570.1975.tb01393.x>
26. Samet JM, Wipfli H, Platz EA, Bhavsar N. A Dictionary of Epidemiology, Fifth Edition: Edited by Miquel Porta. *American Journal of Epidemiology*. 2009, 170(11), 1449-51. <https://doi.org/10.1093/aje/kwp322>
27. Boateng, G. O., Neilands, T. B., Frongillo, E. A., Melgar-Quiñonez, H. R., & Young, S. L. (2018). Best Practices for Developing and Validating Scales for Health, Social, and Behavioral Research: A Primer. *Frontiers in public health*, 6, 149. <https://doi.org/10.3389/fpubh.2018.00149>
28. Lacasse Y, Godbout C, Sériès F. Health-related quality of life in obstructive sleep apnoea. *Eur Respir J*. 2002, 19(3), 499-503. <https://doi.org/10.1183/09031936.02.00216902>
29. Suhr DD. Exploratory or confirmatory factor analysis? 2006. Available from: <https://support.sas.com/resources/papers/proceedings/proceedings/sugi31/200-31.pdf>
30. [dataset] Kueh M, Rahim FF, Rashid A. Data from: Development and validation of the health behavioural intention on smoking cessation to prevent nasopharyngeal cancer in Sarawak, Malaysia based on the Health Belief Model: a cross-sectional study. Dryad Digital Repository, November 18, 2021. <https://doi.org/10.5061/dryad.4tmpg4fbb>
31. Munro BH. *Statistical methods for health care research: lippincott williams & wilkins*; 2005.
32. Xiang B, Wong HM, Cao W, Perfecto AP, McGrath CPJ. Development and validation of the Oral health behavior questionnaire for adolescents based on the health belief model (OHBQAIBM). *BMC Public Health*. 2020, 20(1), 701. <https://doi.org/10.1186/s12889-020-08851-x>
33. Brown TA. *Confirmatory factor analysis for applied research*. New York, NY, US: The Guilford Press; 2006.
34. Fornell C, Larcker DF. Evaluating structural equation models with unobservable variables and measurement error. *Journal of marketing research*. 1981, 18(1), 39-50. <https://doi.org/10.2307/3151312>
35. McGinnis JM, Williams-Russo P, Knickman JR. The case for more active policy attention to health promotion. *Health affairs*. 2002, 21(2), 78-93. <https://doi.org/10.1377/hlthaff.21.2.78>

- 1  
2  
3 36. Cohen RJ, Swerdlik ME, Phillips SM. Psychological testing and assessment: An introduction to  
4 tests and measurement: Mayfield Publishing Co; 1996.
- 5 37. Shamsalinia A, Moradi M, Farahani MA, Masoudi R, Ghadimi R, Rad RE, et al. Designing and  
6 psychometric evaluation of disease-related fear scale (D-RFS) in adults with epilepsy: A sequential  
7 exploratory mixed methods design. *Epilepsy & Behavior*. 2020, 110, 107169.  
8 <https://doi.org/10.1016/j.yebeh.2020.107169>
- 9 38. Schreiber JB, Nora A, Stage FK, Barlow EA, King J. Reporting structural equation modeling  
10 and confirmatory factor analysis results: A review. *The Journal of educational research*. 2006, 99(6),  
11 323-38. <https://doi.org/10.3200/JOER.99.6.323-338>
- 12 39. Kline P. *The handbook of psychological testing*: Psychology Press, 2000.  
13 <https://doi.org/10.4324/9781315812274>
- 14 40. Kline P. *An Easy Guide to Factor Analysis* (1st ed.). 1st edition ed. London. 1994, p. 208.  
15 <https://doi.org/10.4324/9781315788135>
- 16 41. Anderson JC, Gerbing DW. Structural Equation Modeling in Practice: A Review and  
17 Recommended Two-Step Approach. *Psychological Bulletin*. 1988, 103, 411-423.  
18 <http://dx.doi.org/10.1037/0033-2909.103.3.411>  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table S1: Questionnaire to predict health behavioural intention on smoking cessation to prevent nasopharyngeal cancer in Sarawak, Malaysia based on the Health Belief Model: a cross-sectional study (English Version)**

**Section 1: Perceptions towards nose and throat cancer**

Please choose the best answer options to indicate your level of agreement.

Constructs of Health Belief Model	Questions	Strongly disagree	Disagree	Neutral	Agree	Strongly agree
Perceived susceptibility	1. I feel that I will get nose and throat cancer in the future.					
	2. My chances of getting nose and throat cancer are high.					
	3. I cannot avoid myself from getting nose and throat cancer.					
	4. I am worried about getting nose and throat cancer due to family history.					
	5. My smoking habit makes me more likely than average to get nose and throat cancer.					
Perceived seriousness	6. The thought of nose and throat cancer scares me.					
	7. If I had nose and throat cancer, the cost of treatment can be a financial strain.					
	8. Nose and throat cancer would threaten a relationship with my family.					

	9. If I had nose and throat cancer my whole life would change.					
	10. If I developed nose and throat cancer, I would not live long.					
Perceived benefits	11. Quit smoking decreases my chance of getting nose and throat cancer.					
	12. Quit smoking decreases my chance of dying from nose and throat cancer.					
	13. Quit smoking can improve my health.					
	14. I feel less anxious about nose and throat cancer if I quit smoking.					
Perceived barriers	15. It is difficult to quit tobacco smoking (e.g. peer pressure).					
	16. I feel anxious without smoking.					
	17. Tobacco smoking relieves my stress.					
	18. I experience headache without smoking.					
	19. I experience excessive salivation without smoking.					
	20. I think getting nose and throat cancer is destiny and quitting smoking will not change it.					
Cues to action	21. I will stop smoking if I have social support.					



	22. I will stop smoking if there are information sources that reminds me. Examples of sources include: the internet, newspapers, radio and TV.					
	23. I will stop smoking if I have the will to change.					
	24. I will stop smoking if I know the diseases related to smoking.					
	25. I will stop smoking if there are health professionals to assist me.					
Self-efficacy	26. I can refuse to smoke when I am thinking about difficult problem.					
	27. I can refuse the urge to smoke.					
	28. I can refuse to smoke when I see someone else smoking.					
	29. I can refuse to smoke when offered by my friends/ family.					
	30. I can refuse from buying cigarettes when I have extra pocket money.					

## Section 2: Health Behavioural Intention to quit smoking

Please choose the best answer options to indicate your level of agreement.

Statements	Strongly disagree	Disagree	Neutral	Agree	Strongly agree
------------	-------------------	----------	---------	-------	----------------

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1. I would like to lead a healthier lifestyle to prevent nose and throat cancer.					
2. I am trying to quit smoking to prevent nose and throat cancer at this time.					
3. I plan to quit smoking to prevent nose and throat cancer within six months.					
4. I would like to quit smoking to prevent nose and throat cancer but have never really tried.					

For peer review only

**Table S2: Questionnaire to predict health behavioural intention on smoking cessation to prevent nasopharyngeal cancer in Sarawak, Malaysia based on the Health Belief Model: a cross-sectional study (Malay Version)**

**Bahagian 1: Persepsi terhadap kanser hidung dan tekak.**

Sila bulatkan dengan pilihan jawapan terbaik untuk menunjukkan tahap persetujuan anda.

Domain Model Kepercayaan Kesihatan	Soalan	Sangat tidak setuju	Tidak setuju	Kurang bersetuju	Setuju	Sangat setuju
Kepercayaan kepada tiada daya tahan	1. Saya merasakan bahawa saya akan mendapat kanser pangkal hidung pada masa akan datang.					
	2. Peluang saya mendapat kanser pangkal hidung adalah tinggi.					
	3. Saya tidak dapat mengelakkan diri daripada mendapat kanser pangkal hidung.					
	4. Saya bimbang terkena kanser pangkal hidung kerana ahli keluarga saya menghadapi masalah ini.					
	5. Tabiat merokok saya menyebabkan saya lebih berisiko menghidap kanser pangkal hidung.					
Kepercayaan kepada bahaya	6. Risiko dan kesan-kesan kanser pangkal hidung menakutkan saya.					
	7. Jika saya mempunyai kanser pangkal hidung, kos					

	rawatan akan menjadi beban kewangan keluarga saya.					
	8. Kanser pangkal hidung akan merosakkan hubungan antara ahli keluarga saya.					
	9. Jika saya mempunyai kanser pangkal hidung, kehidupan saya akan diubah.					
	10. Jika saya mempunyai kanser pangkal hidung, saya tidak akan hidup lama.					
Kepercayaan kepada manfaat	11. Berhenti merokok akan mengurangkan peluang saya mendapat kanser pangkal hidung.					
	12. Berhenti merokok akan mengurangkan risiko kematian disebabkan kanser pangkal hidung.					
	13. Berhenti merokok amat penting untuk meningkatkan kesihatan saya.					
	14. Berhenti merokok akan mengurangkan kerisauan saya terhadap kanser pangkal hidung.					
Kepercayaan kepada halangan	15. Saya berasa sukar untuk menghentikan tabiat merokok atas					

	sebab tekanan rakan sebaya dan lain-lain.					
	16. Saya akan berasa bimbang akan sesuatu tanpa merokok.					
	17. Merokok menghilangkan tekanan saya.					
	18. Jika saya tidak merokok, saya akan mengalami sakit kepala					
	19. Jika saya tidak merokok, saya akan mengalami air liur berlebihan.					
	20. Saya rasa mendapat kanser pangkal hidung adalah takdir dan berhenti merokok tidak akan mengubahnya.					
Isyarat untuk bertindak	21. Jika saya mempunyai sokongan sosial, saya akan berhenti merokok.					
	22. Jika beberapa sumber maklumat mengingatkan saya, saya akan berhenti merokok. Contoh sumber maklumat termasuk internet, surat khabar, radio dan TV.					
	23. Saya akan berhenti merokok sekiranya saya mempunyai kemahuan untuk berubah.					

	24. Menyedari bahaya merokok akan membantu saya berhenti merokok.					
	25. Saya akan berhenti merokok sekiranya ahli profesional kesihatan membantu saya					
Keberkesanan diri	26. Saya boleh menolak merokok apabila saya ingin memikirkan masalah yang sukar.					
	27. Saya boleh menolak merokok apabila saya mempunyai keinginan untuk merokok.					
	28. Saya boleh menolak merokok apabila saya melihat orang lain merokok.					
	29. Saya boleh menolak merokok apabila kawan/ keluarga saya mengajak saya untuk merokok.					
	30. Saya boleh menolak membeli rokok apabila saya mempunyai lebih wang saku.					

## Bahagian 2: Tingkah laku untuk berhenti merokok demi kesihatan

Sila bulatkan dengan pilihan jawapan terbaik untuk menunjukkan tahap persetujuan anda.

Soalan	Sangat tidak bersetuju	Tidak setuju	Kurang bersetuju	Setuju	Sangat setuju
--------	------------------------	--------------	------------------	--------	---------------

1					
2					
3					
4	1. Saya akan menjalani gaya				
5	hidup yang lebih sehat untuk				
6	mencegah kanker pangkal hidung.				
7	2. Saya sedang berusaha untuk				
8	berhenti merokok untuk				
9	mengurangkan risiko kanker				
10	pangkal hidung pada masa ini.				
11	3. Saya merancang untuk				
12	berhenti merokok untuk				
13	mengurangkan risiko kanker				
14	pangkal hidung dalam masa enam				
15	bulan.				
16	4. Saya ingin berhenti merokok				
17	untuk mengurangkan risiko				
18	kanker pangkal hidung tetapi				
19	tidak pernah mencuba.				
20					
21					
22					
23					
24					
25					
26					
27					
28					
29					
30					
31					
32					
33					
34					
35					
36					
37					
38					
39					
40					
41					
42					
43					
44					
45					
46					
47					
48					
49					
50					
51					
52					
53					
54					
55					
56					
57					
58					
59					
60					

# Reporting checklist for cross sectional study.

Based on the STROBE cross sectional guidelines.

## Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the STROBE cross sectional reporting guidelines, and cite them as:

von Elm E, Altman DG, Egger M, Pocock SJ, Gotsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.

	Reporting Item	Page Number
<b>Title and abstract</b>		
Title	<a href="#">#1a</a> Indicate the study's design with a commonly used term in the title or the abstract	3
Abstract	<a href="#">#1b</a> Provide in the abstract an informative and	3



1		balanced summary of what was done and what	
2			
3		was found	
4			
5			
6	<b>Introduction</b>		
7			
8			
9	Background /	<a href="#">#2</a> Explain the scientific background and rationale	4-5
10			
11	rationale	for the investigation being reported	
12			
13			
14	Objectives	<a href="#">#3</a> State specific objectives, including any	5
15		prespecified hypotheses	
16			
17			
18			
19	<b>Methods</b>		
20			
21			
22			
23	Study design	<a href="#">#4</a> Present key elements of study design early in	6
24		the paper	
25			
26			
27			
28	Setting	<a href="#">#5</a> Describe the setting, locations, and relevant	6
29		dates, including periods of recruitment,	
30		exposure, follow-up, and data collection	
31			
32			
33			
34			
35			
36	Eligibility criteria	<a href="#">#6a</a> Give the eligibility criteria, and the sources and	6
37		methods of selection of participants.	
38			
39			
40			
41		<a href="#">#7</a> Clearly define all outcomes, exposures,	6-7
42		predictors, potential confounders, and effect	
43		modifiers. Give diagnostic criteria, if applicable	
44			
45			
46			
47			
48			
49	Data sources /	<a href="#">#8</a> For each variable of interest give sources of	7-8
50		data and details of methods of assessment	
51	measurement	(measurement). Describe comparability of	
52		assessment methods if there is more than one	
53		group. Give information separately for for	
54			
55			
56			
57			
58			
59			
60			

exposed and unexposed groups if applicable.

1			
2			
3			
4	Bias	<a href="#">#9</a> Describe any efforts to address potential	7-8. We involved experts
5			
6		sources of bias	and participants of
7			
8			different background and
9			
10			ethnic groups in hopes to
11			
12			reduce biasness.
13			
14			
15			
16	Study size	<a href="#">#10</a> Explain how the study size was arrived at	14
17			
18			
19	Quantitative	<a href="#">#11</a> Explain how quantitative variables were	8
20			
21	variables	handled in the analyses. If applicable, describe	
22			
23		which groupings were chosen, and why	
24			
25			
26	Statistical	<a href="#">#12a</a> Describe all statistical methods, including those	7-8
27			
28	methods	used to control for confounding	
29			
30			
31			
32	Statistical	<a href="#">#12b</a> Describe any methods used to examine	8
33			
34	methods	subgroups and interactions	
35			
36			
37	Statistical	<a href="#">#12c</a> Explain how missing data were addressed	N/A. No missing data was
38			
39	methods		collected.
40			
41			
42	Statistical	<a href="#">#12d</a> If applicable, describe analytical methods	8
43			
44	methods	taking account of sampling strategy	
45			
46			
47			
48	Statistical	<a href="#">#12e</a> Describe any sensitivity analyses	N/A
49			
50	methods		
51			
52			
53	<b>Results</b>		
54			
55			
56	Participants	<a href="#">#13a</a> Report numbers of individuals at each stage of	N/A. Do not have a list of
57			
58			
59			
60			

study—eg numbers potentially eligible, numbers potentially  
 examined for eligibility, confirmed eligible, eligible.  
 included in the study, completing follow-up,  
 and analysed. Give information separately for  
 for exposed and unexposed groups if  
 applicable.

15	Participants	<a href="#">#13b</a>	Give reasons for non-participation at each stage	N/A
20	Participants	<a href="#">#13c</a>	Consider use of a flow diagram	N/A. Do not have a list of numbers potentially eligible.
28	Descriptive data	<a href="#">#14a</a>	Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders. Give information separately for exposed and unexposed groups if applicable.	8-9
40	Descriptive data	<a href="#">#14b</a>	Indicate number of participants with missing data for each variable of interest	N/A. No missing data was collected
46	Outcome data	<a href="#">#15</a>	Report numbers of outcome events or summary measures. Give information separately for exposed and unexposed groups if applicable.	N/A. This study focuses on validating the questionnaire with a series of analysis.
55	Main results	<a href="#">#16a</a>	Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their	N/A. This study focuses on validating the

1		precision (eg, 95% confidence interval). Make	questionnaire with a
2			
3		clear which confounders were adjusted for and	series of analysis.
4			
5		why they were included	
6			
7			
8	Main results	<a href="#">#16b</a> Report category boundaries when continuous	N/A. This study focuses
9		variables were categorized	on validating the
10			questionnaire with a
11			series of analysis.
12			
13			
14			
15			
16			
17			
18	Main results	<a href="#">#16c</a> If relevant, consider translating estimates of	N/A. This study focuses
19		relative risk into absolute risk for a meaningful	on validating the
20		time period	questionnaire with a
21			series of analysis.
22			
23			
24			
25			
26			
27			
28	Other analyses	<a href="#">#17</a> Report other analyses done—e.g., analyses of	10-13
29		subgroups and interactions, and sensitivity	
30		analyses	
31			
32			
33			
34			
35	<b>Discussion</b>		
36			
37			
38	Key results	<a href="#">#18</a> Summarise key results with reference to study	13-14
39		objectives	
40			
41			
42			
43			
44	Limitations	<a href="#">#19</a> Discuss limitations of the study, taking into	14
45		account sources of potential bias or	
46		imprecision. Discuss both direction and	
47		magnitude of any potential bias.	
48			
49			
50			
51			
52			
53			
54	Interpretation	<a href="#">#20</a> Give a cautious overall interpretation	14
55		considering objectives, limitations, multiplicity	
56			
57			
58			
59			
60			

of analyses, results from similar studies, and  
other relevant evidence.

Generalisability [#21](#) Discuss the generalisability (external validity) of the study results 14

## Other

## Information

Funding [#22](#) Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based 14

## Notes:

- 9: 5 - 6. We involved experts and participants of different background and ethnic groups in hopes to reduce biasness.
- 12c: N/A. No missing data was collected.
- 13a: N/A. Do not have a list of numbers potentially eligible.
- 13c: N/A. Do not have a list of numbers potentially eligible.
- 14b: N/A. No missing data was collected
- 15: N/A. This study focuses on validating the questionnaire with a series of analysis.
- 16a: N/A. This study focuses on validating the questionnaire with a series of analysis.
- 16b: N/A. This study focuses on validating the questionnaire with a series of analysis.

- 1 • 16c: N/A. This study focuses on validating the questionnaire with a series of analysis. The  
2 STROBE checklist is distributed under the terms of the Creative Commons Attribution License  
3 CC-BY. This checklist was completed on 19. September 2021 using  
4  
5 <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with  
6  
7 [Penelope.ai](#)  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

# BMJ Open

## Development and validation of the Health Belief Model questionnaire to promote smoking cessation for nasopharyngeal cancer prevention: a cross-sectional study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-057552.R2
Article Type:	Original research
Date Submitted by the Author:	07-Jul-2022
Complete List of Authors:	Kueh, Martin; RCSI & UCD Malaysia Campus, Department of Public Health Medicine Rahim, Fairuz Fadzilah; RCSI & UCD Malaysia Campus, Department of Public Health Medicine Rashid, Abdul; RCSI & UCD Malaysia Campus, Public Health Medicine
<b>Primary Subject Heading</b>:	Public health
Secondary Subject Heading:	Public health, Smoking and tobacco, Oncology
Keywords:	PUBLIC HEALTH, Head & neck tumours < ONCOLOGY, Epidemiology < ONCOLOGY

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.



1  
2  
3 **Development and validation of the Health Belief Model questionnaire to promote smoking**  
4 **cessation for nasopharyngeal cancer prevention: a cross-sectional study**

5 Martin Kueh<sup>1</sup>, Fairuz Fadzilah Rahim<sup>1</sup> & Abdul Rashid<sup>1</sup>  
6  
7

8 <sup>1</sup>Department of Public Health Medicine, RCSI & UCD Malaysia Campus, No.4, Jalan Sepoy Lines, 10450  
9 George Town, Penang Malaysia  
10

11 Correspondence: Martin Kueh, Department of Public Health Medicine, RCSI & UCD Malaysia Campus,  
12 No.4, Jalan Sepoy Lines, 10450 George Town, Penang Malaysia. Tel: 6016-879 2269. Email:  
13 [martin1kueh@hotmail.com](mailto:martin1kueh@hotmail.com)  
14  
15

16  
17  
18 **Abstract**

19 **Objective** Lifestyle-induced nasopharyngeal carcinoma (NPC) is a serious but preventable risk factor.  
20 This study serves to develop and validate a questionnaire that aims to predict the health behavioural  
21 intention on smoking cessation in Sarawak, Malaysia using the Health Belief Model (HBM).  
22  
23

24 **Design** A cross-sectional study  
25

26 **Setting** Urban and suburban areas in Sarawak, Malaysia.  
27

28 **Participants** The preliminary items of the instrument were developed after extensive literature review.  
29 The instrument was translated into the Malay language using the forward-backwards method before  
30 commencing with the content validity by a panel of 10 experts. Face validity was done both  
31 quantitatively and qualitatively by 10 smokers. The construct validity of the instrument was evaluated  
32 through exploratory factor analysis (EFA) and confirmatory factor analysis (CFA). A total of 100  
33 smokers participated in phase 1 for EFA, while 171 smokers participated in phase 2 for CFA. Internal  
34 consistency was measured using Cronbach's alpha coefficients to evaluate the reliability.  
35  
36

37 **Results** In the exploratory stage, the factor loading of each item remained within the acceptable  
38 threshold. The final revised CFA yielded appropriate fit of the seven-factor model with the following  
39 model fit indexes: Chi-Square: 641.705; df= 500; P< 0.001; CFI = 0.953; TLI: 0.948; RMSEA= 0.041.  
40 Satisfactory convergent validity and divergent validity were shown, with the exception of one pairwise  
41 construct. The internal reliability of these scales was above the desirable threshold, with Cronbach's  
42 alpha coefficients ranging from 0.705 to 0.864 and 0.838 to 0.889 in phase 1 and 2, respectively.  
43  
44

45 **Conclusions** The study substantiated the instrument to be valid and reliable for predicting smokers'  
46 health behavioural intention to reduce cancer risk. The instrument is made up of 34 items, categorised  
47 into two sections, six HBM constructs and health behavioural intention. The instrument can be utilised  
48 for other smoking cessation-related cancers in different at-risk populations.  
49

50 **Keywords:** tobacco smoking, cancer, health promotion, nasopharyngeal cancer, health belief model,  
51 development, validation, smoking cessation  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Article Summary

### Strengths and limitations of this study

1. This study established a novel instrument to assess smokers' health behavioural intention to reduce NPC risks, based on a well-known framework in a series of systematic validation stages. This instrument can potentially be applied to other smoking-related cancers as well.
2. Face validity was undertaken both qualitatively and quantitatively to sufficiently reflect the demographic during the assessments of psychological constructs. The validation was markedly aided by experts' evaluations.
3. This study was conducted in two phases, involving both urban and suburban smokers, to examine concept validity, convergent validity, and divergent validity.
4. The study's generalizability may be limited by the smokers' cultural perspective, hence, further studies on smokers from different cultures will be needed to assess the instrument's psychometric properties.

### Introduction

According to the World Health Organization, tobacco smoking is a public health concern that accounts for over 8 million deaths per year and is the leading avoidable cause of illness, disability, and death globally [1]. Annually, exposure to smoking is associated with 2.4 million deaths from cancer throughout the world [2]. The report from the Surgeon General of the United States of America (USA) associating smoking and cancer was a watershed moment in public health towards tobacco's adverse effects on human health. This was followed by the subsequent discovery that tobacco smoke comprises approximately 7,000 compounds, 72 of which are carcinogenic [3, 4]. Tobacco use is now causally associated with at least 20 cancer types. There are wide-ranging immediate and long-term health benefits accompanying smoking cessation [2]. However, the harmful consequences of tobacco smoking are widely neglected or underestimated, despite the fact that it remains a significant public health hazard among the impoverished, and marginalised, as well as those in developing nations, which bear a disproportionate share of the burden [5].

Cancer is a leading cause of death as well as a major obstacle to improving lifespan in every country [6]. There is an approximately 1% reduction in the overall cancer mortality rate across both sexes in both high- and low-income countries [7]. However, there are variations in the frequency and distribution of aetiological aspects such as socioeconomic, geographical, genetic, biological, ethnic, social, and physical factors, as well as disparities across cancer types [7, 8]. For instance, nasopharyngeal cancer (NPC) is uncommon but unique among head and neck cancers with its own distinct epidemiological & risk factors. Global data from the World Health Organization illustrates poorer outcomes of NPC in endemic areas like Southeast Asia which has an unbalanced global burden of 67% [9].

In Malaysia, NPC is a nationwide public health concern and the fifth leading form of cancer, amounting to 4,597 new diagnoses of NPC for the 2012-2016 period. A recent report from the Malaysian National Cancer Registry reported that the lifetime risk of developing NPC among men and women is 1 in 175 and 1 in 482, respectively [10]. There is a substantial geographical variance within the country, with Sarawak exhibiting a higher prevalence rate of NPC. A previous study has shown a significant high age-standardised rate in males (13.5/100,000, 95% Confidence Interval = 12.2 – 15.0) and females

1  
2  
3 (6.2/100,000, 95% CI= 5.7-6.7). The high-risk ethnic groups in Sarawak which include Bidayuh, Chinese,  
4 Iban, Malays and Melanau collectively rank top globally. In particular, the risk among the Bidayuh  
5 ethnic population, which is a native indigenous group, exceeds the risk for the male and female  
6 general population in Sarawak by 2.3 times and 1.9 times respectively [11].  
7

8  
9 This trend has been ascribed to potential risk factors, which include Epstein-Barr virus, genetic  
10 susceptibility, consumption of food with nitrous compounds and volatile nitrosamines, and complex  
11 interaction with environmental factors [12]. Among the many risk factors that are associated with NPC,  
12 tobacco smoking is the most important modifiable cause of NPC [13, 14]. A meta-analysis 32  
13 epidemiological studies (28 case-control studies and 4 cohort studies) on the association of tobacco  
14 smoking and NPC from 1979 to 2011 reported that tobacco-correlated NPC cases were 60% higher  
15 compared to non-smokers [15]. The Malaysian National Health and Morbidity Survey 2015 showed  
16 that the prevalence of tobacco smoking among the population in Sarawak was 25.4%. The native  
17 indigenous male (61.2%) and female (10.7%) smokers in Sarawak were among the highest nationwide  
18 [16]. Rahman et al (2015) indicated that the average number of cigarettes smoked per day in Sarawak  
19 was 13.6 [17]. This lifestyle-induced NPC is a serious concern, and necessitates a preventative strategy  
20 centred on modifying health risk behaviours.  
21  
22

23  
24 Despite the robust establishment of cumulative impact of tobacco smoking on the risk of cancer, in  
25 Malaysia, there is still a paucity of published studies and research to evaluate the effectiveness of  
26 comprehensive strategies to promote cancer prevention among smokers. It is imperative to create a  
27 questionnaire that focuses on behavioural factors and is customised to the interests of local smokers  
28 to risk of cancer. The Health Belief Model (HBM) is an approachable theoretical model that aids in the  
29 understanding of the individual's or a smoker's belief on the health-related behavioural intention [18,  
30 19]. This HBM can predict the smokers' effort to improve health or their health-seeking behaviours  
31 for the prevention of NPC. This study serves to develop and validate a health behaviour model (HBM)-  
32 based questionnaire that aims to predict the health behavioural intention of smokers and their  
33 perspective and motivation towards smoking cessation.  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### Conceptual Framework

The Health Belief Model (HBM) is the underpinning conceptual framework for this study to focus on psychological variables to predict health behavioural intention. Developed in the 1950s by social psychologists at the United States Public Health Service, the Health Belief Model (HBM) is currently one of the most extensively used cognitive model and theoretical framework to help researchers understand and predict health behaviours in the population and ultimately guide health promotion and interventions activities [18, 19]. A large volume of studies conducted in numerous countries, both in developed and developing countries, have utilized HBM to examine health-promoting behaviours for the prevention of different cancers [20-22]. The HBM is a value-expectancy theory, based on the hypothesis of Lewin et al that highlights the influence of two variables on behaviour: 1) the value that a person places on the outcome of the behaviour and 2) the person's perception of how likely the behaviour will lead to that outcome, in the event of an illness (19). Having evolved over the past decades, HBM currently consists of 6 elements: i) perceived susceptibility, ii) perceived severity, iii) perceived benefits, iv) perceived barriers, v) cues to action, and vi) self-efficacy [23].

The first four refer to a person's subjective perceptions regarding 1) his/her risk of getting the disease; 2) how severe the consequences are of getting the disease; 3) the benefits from performing a health behaviour in preventing, curing, or managing the disease; and 4) obstacles to that health behaviour, e.g. financial and time costs, side effects, and so on (23). "Cue to action" is the stimulus, which may be internal (e.g., physical sensations) or external (e.g., friends with the disease, social media), that is required for that health behaviour to occur, and "self-efficacy" refers to the person's confidence on how capable he/she is to successfully undertake that health behaviour [19, 23].

---

## **Methods**

### **Study design and setting**

A cross-sectional study was conducted in Sarawak, Malaysia in two phases: phase 1 from October 2020 to January 2021 and phase 2 from January to April 2021. Sarawak is the largest Malaysian state situated on the island of Borneo with a population of more than 2.6 million, made up of 26 different ethnic groups. Sarawak is divided into twelve divisions, each of which is further divided into districts and sub-districts. The two divisions selected for the study were Miri and Bintulu, which had the respective populations of 433,800 and 266,200.

The sample population in phase 1 were residents residing in urban and suburban areas in Miri, Sarawak. Phase 2 mainly involved residents of Bintulu, Kuala Baram (a federal constituency in Miri Division), and remote rural areas in Miri. They were mainly local employees working in the agricultural industry. Data were collected by eight trained research assistants. All research assistants were given a crash course in the research aims, methodology and data collection, as well as a trial run to simulate real-world situations. Prior to the distribution of the questionnaires, participants were briefed regarding the objective and methodology of the study, as well as the benefits and risks involved. Involvement in this study was entirely voluntary. Upon clarifying the study details, informed consent was obtained from each participant. The anonymity of the respondents' details is assured. The research assistants provided clarification to smokers who requested assistance. The methodology of the study and data collection were recorded precisely and accurately throughout the process of the research.

The inclusion criteria were: 1) 18 years old and above, 2) smoked for at least a year, and 3) is a Sarawakian. Participants who did not consent to participate, were pregnant, or smoked e-cigarettes only were excluded from this study.

### **Patient and Public Involvement**

No patient was involved in this study.

### **Instrument development and validation**

The questionnaire was self-administered based on prior validated studies. A search was conducted using the National Library of Medicine (PubMed), Google Scholar and Cochrane Library databases by exploring various keywords: health belief model, nasopharyngeal cancer, cancer, smokers, smoking behaviours/habit, and questionnaire/tools/instruments. Questionnaires and prior literature were examined primarily, and explicitly on smokers around NPC prevention using HBM. The initial questionnaire consisted of 41 items.

The questionnaire was developed in English and translated to Malay by two local fluent bilingual translators. An experienced researcher, whose mother tongue is Malay, compared the Malay version of the questionnaire to the English version. A 'back-translation' approach to English was taken independently by another two bilingual translators based on the Beaton-recommended guidelines [24].

1  
2  
3 To determine the content validity, 10 healthcare professionals including public health experts, hospital  
4 directors, and health officers were invited to evaluate the survey instrument. Using Lawshe's model,  
5 a questionnaire was designed and organized to assist and allow the panellists to express clearly their  
6 views on the importance of including different components in a model. Experts received attachments  
7 of the questionnaire via email, which was graded on a three-point scale: essential, useful but not  
8 essential, and not essential. Based on Lawshe's table, items with a CVR value greater than 0.62 were  
9 retained [25]. To minimise ambiguity, the experts evaluated each item's accuracy, phrasing and  
10 grammar as well as their relevance to the construct. Modifications were made for subsequent analysis  
11 based on the experts' comments and suggestions. Overall, 8 items were deleted, 2 items were  
12 rephrased and 1 item was allocated into a different construct.  
13  
14  
15

16 Face validity was evaluated through a pilot study by 10 local smokers of different ethnic backgrounds,  
17 both qualitatively and quantitatively. Smokers who participated in the pilot study were exempted  
18 from the main study. The pilot study is conducted on a small-scale basis to ascertain the feasibility of  
19 the proposed larger study [26]. In the qualitative stage, cognitive interviews were conducted face-to-  
20 face individually to obtain participants' feedback on their comprehension and answers. Items which  
21 were not well understood were identified from the cognitive interview [27]. Minor revisions were  
22 made to better suit a linguistically and culturally diverse context. Based on the smokers' perspective,  
23 an item-oriented person's faith or spirituality to own health was also included. With the consensus of  
24 the researchers, an item was added, 'I think getting nose and throat cancer is my destiny and quitting  
25 smoking will not change it'. In the quantitative stage, a survey was disseminated based on a Likert  
26 scale of 1 (least importance) to 5 (extremely important) to determine the clinical impact of each item.  
27 The importance score was calculated based on the "clinical impact method" in which the clinical  
28 impact of each item was determined from the proportion of participants who identified it as important.  
29 This technique was chosen for better clarity where the items were ranked according to their impact  
30 score. The mean importance score of each item was computed using the following formula: Impact  
31 Score = Frequency (Proportion) x Importance. Factors were kept if the Impact Score equal or more  
32 than 1.5. These factors were defined as deemed suitable and kept for further evaluation [28]. In the  
33 current study, the impact score for each item ranged from 1.7 to 4.6, therefore, no item was  
34 eliminated.  
35  
36  
37  
38  
39

40 Subsequently, in the main study, to determine the construct validity, exploratory and confirmatory  
41 factor analyses were performed in two periods. In the first period, EFA (n = 100) was used to determine  
42 the number of latent factors or the relationships between the common factors. The model was later  
43 adjusted in the second period with CFA (n = 171) via structural equations using AMOS. CFA confirmed  
44 the overall fit of the model and indicated that the measures were in the acceptable range [29].  
45 Convergent validity and discriminant validity were also carried out in phase 2. The flow diagram for  
46 the questionnaire development and validation is shown in Figure 1.  
47  
48

#### 49 **Final scoring of the instrument:**

50 In the main study, the total mean score for each HBM component was formulated on the five-point  
51 Likert scale options from strongly disagree to strongly agree, with scores ranging from 1 to 5 points.  
52 With the exception of 'Perceived Barriers,' which is inversely proportional, a greater score reflects a  
53 firmer desire to quit smoking.  
54  
55  
56

#### 57 **Ethical considerations:**

58 This study was approved by the Joint Penang Ethics Committee (Approval no. JPEC 20 0027). The  
59 informed consent of all participants was obtained voluntarily, and data confidentiality and storage are  
60 assured.

### Data management:

The data was processed in Microsoft Excel before being analysed in SPSS 26.0 and AMOS 23.0 [30]. Listwise deletion approach was done for missing data of less than 2%. Socio-demographic characteristics are presented as number and percentage distribution. Cronbach's alpha coefficients were used to determine internal consistency. Exploratory Factor Analysis (EFA) and Confirmatory Factor Analysis (CFA) were used to test the construct validity of each construct. Specifically, EFA was evaluated in phase 1 and CFA in phase 2. A p-value below 0.05 was deemed to be statistically significant.

EFA was performed in phase 1 to reveal the fundamental structure of a large set of variables [29]. The factors were extracted using principal component analysis with a varimax rotation. The Kaiser-Meyer-Olkin (KMO) > 0.6 and Bartlett's test for sphericity ( $p < 0.05$ ) were used for adequacy and item checking. All loading factors below 0.3 were excluded from the constructs [31].

CFA was performed in phase 2 to assess the data integrity and the structural model [29]. The acceptable level of standardised factor loading was set at 0.5 and above to ensure a satisfactory association between items and corresponding factors [32]. Different fit indices were utilised to estimate the model fit. These include a comparative fit index (CFI) of > 0.90, Tucker-Lewis Index (TLI) > 0.90 and root mean square error of approximation (RMSEA) < 0.05 [33]. Additionally, convergent validity and discriminant validity were evaluated based on the composite reliability (CR) and average variance extracted (AVE). The HBM components were analysed with the minimum and maximum scores, total mean score and standard deviation (SD).

### Results:

A total of 100 and 171 smokers participated in phase 1 and 2 of the study, respectively. The response rate for phase 1 was 100%, whereas in phase 2 the response rate was 98.3% (171/174). The majority of the participants were males (Phase 1, 86.0%; Phase 2, 89.5%) and were in the 30-39 age group (Phase 1, 40.0%; Phase 2, 40.9%). A little over a third of the participants smoked for more than 10 years for both phase 1 (37%) and phase 2 (40.4%). In phase 1, most of the participants were Iban (34%), followed by Malay (19%), Chinese (18%), Others (13%), Melanau (9%) and Bidayuh (7%). Most of the participants in phase 2 were Chinese (33.9%), followed by Iban (24.6%), Malay (12.3%), Bidayuh (9.9%), Melanau (9.9%) and Others (9.4%). Details of the smokers' demographic information is presented in Table 1.

**Table 1: Demographic characteristics of participants**

	Phase 1 (n=100)		Phase 2 (n=171)	
	Number	Percentage (%)	Number	Percentage (%)
Age				
18-29	34	34.0	46	26.9
30-39	40	40.0	70	40.9
40-49	14	14.0	43	25.1
50-64	12	12.0	10	5.8
65 and above	0	0.0	2	1.2
Gender				
Male	86	86.0	153	89.5
Female	14	14.0	18	10.5

Ethnic groups				
Malay	19	19.0	21	12.3
Chinese	18	18.0	58	33.9
Bidayuh	7	7.0	17	9.9
Iban	34	34.0	42	24.6
Melanau	9	9.0	17	9.9
Others	13	13.0	16	9.4
Years of smoking				
1-5 years	32	32.0	44	25.7
6-10 years	31	31.0	58	33.9
More than 10 years	37	37.0	69	40.4

In phase 1, Kaiser-Meyer-Olkin Measure of Sampling Adequacy was 0.697 and Barlett's test of the sphericity was significant ( $\chi^2 = 1,746$ ,  $p$ -value < 0.001). EFA was conducted to analyse the factor structure with principal component analysis with a varimax rotation. A decision was made to go for 7-factor structures since there is clarity of 7 constructs. The EFA found that 7 variables had eigenvalues larger than Kaiser's threshold of 1 and explained 63.0% of the variance when combined. Factor loadings higher than 0.3 were found in all the items. Four items had cross-loading with values greater than 0.3, which are PBar5, HBI2, HBI3 & HBI4. All items remained because the contents of the items were regarded as relevant based on the decision and judgment of the researchers. Table 2 shows the EFA with total items and the factor loading of each construct for the 7-factor model.

**Table 2: Result of Exploratory Factor Analysis in phase 1 (n = 100)**

Constructs	Items	Component						
		1	2	3	4	5	6	7
Perceived Susceptibility	PSus1			0.665				
	PSus2			0.750				
	PSus3			0.810				
	PSus4			0.548				
	PSus5			0.736				
Perceived Severity	PSev1						0.558	
	PSev2						0.720	
	PSev3						0.744	
	PSev4						0.843	
	PSev5						0.730	
Perceived Benefit	PBen1	0.767						
	PBen2	0.765						
	PBen3	0.763						
	PBen4	0.792						
Perceived Barrier	PBar1					0.594		
	PBar2					0.725		
	PBar3					0.658		
	PBar4					0.709		
	PBar5					0.590		
	PBar6					0.617		
Cue to action	CUE1				0.721			



	CUE2				0.584			
	CUE3				0.736			
	CUE4				0.723			
	CUE5				0.745			
Self-efficacy	EFF1		0.721					
	EFF2		0.730					
	EFF3		0.770					
	EFF4		0.868					
	EFF5		0.625					
Health Behavioural Intention	HBI1							0.681
	HBI2							0.307
	HBI3							0.733
	HBI4							0.596
Rotation Sums of Squared Loading								
Total		3.469	3.371	3.246	3.072	3.071	3.012	2.185
Percentage of Variance		10.203	9.913	9.548	9.034	9.032	8.859	6.425
Cumulative percentage		10.203	20.116	29.664	38.698	47.730	56.588	63.014

CFA was performed in phase 2 to assess whether the seven-factor model indicated by the EFA could sufficiently represent the data. The items in their respective constructs were loaded between 0.586 and 0.898 (Table 3). For the model's fitness to increase, items with less than 0.6 and a MI of more than 10 should have been eliminated. However, they were kept because they were essential for the conceptual framework. Before arriving at the final model, 6 pairs of correlated errors were added to improve robustness. The resulting model was suitable for testing, as evidenced by the following model fit indexes: Chi Square: 641.705; df= 500; P< 0.001; CFI = 0.953; TLI: 0.948; RMSEA= 0.041 (90% CI 0.031 to 0.050).

**Table 3: Result of Confirmatory Factor Analysis in phase 2 (n = 171)**

Constructs	Items	Factor Loadings	AVE	CR
Perceived Susceptibility	PSus1	0.898	0.577	0.871
	PSus2	0.819		
	PSus3	0.739		
	PSus4	0.685		
	PSus5	0.683		
Perceived Severity	PSev1	0.680	0.597	0.881
	PSev2	0.675		
	PSev3	0.806		

	PSev4	0.867		
	PSev5	0.766		
	PBen1	0.752		
	PBen2	0.812		
	PBen3	0.740		
Perceived Benefit	PBen4	0.733	0.603	0.858
	PBar1	0.586		
	PBar2	0.670		
	PBar3	0.626		
	PBar4	0.886		
	PBar5	0.878		
Perceived Barrier	PBar6	0.770	0.572	0.888
	CUE1	0.646		
	CUE2	0.721		
	CUE3	0.727		
	CUE4	0.767		
Cue to action	CUE5	0.723	0.512	0.839
	EFF1	0.645		
	EFF2	0.694		
	EFF3	0.827		
	EFF4	0.859		
Self-efficacy	EFF5	0.744	0.574	0.869
	HBI1	0.654		
	HBI2	0.836		
	HBI3	0.867		
Health Behavioural Intention	HBI4	0.773	0.617	0.864

The AVE and CR values, which are listed in [Table 3](#), were obtained after the structural model's fit was investigated to check if the items were loaded appropriately. The AVE readings were all over the cut-off value of 0.5, ranging from 0.512 to 0.617. The CR values were all over the cut-off value of 0.7, ranging from 0.839 to 0.888. All seven constructs featured sufficient convergent validity.

Discriminant validity was evaluated using Fornell-Larcker criteria by comparing the squared correlations and AVE scores for each of the pairwise constructs [34]. With the exception of Perceived Benefit < — > Cue to action, all paired constructs have shown established discriminant validity ([Table 4](#)).

**Table 4: Result of Discriminant Validity in phase 2 (n = 171)**

	Factor Correlation	Correlation Squared	Discriminant validity
Perceived Susceptibility<-->Perceived Severity	.312	0.097	Established
Perceived Susceptibility <-->Perceived Benefit	.260	0.068	Established
Perceived Susceptibility <-->Perceived Barrier	.204	0.042	Established
Perceived Susceptibility <-->Cue to Action	.172	0.030	Established
Perceived Susceptibility <-->Self-Efficacy	.236	0.056	Established
Perceived Severity <--> Perceived Benefit	.575	0.331	Established
Perceived Severity <--> Perceived Barrier	-.042	0.176	Established
Perceived Severity <--> Cue to Action	.238	0.057	Established
Perceived Severity <--> Self-Efficacy	.257	0.066	Established
Perceived Benefit <--> Perceived Barrier	-.085	0.007	Established
Perceived Benefit <--> Cue to Action	.826	0.682	Not Established
Perceived Benefit <--> Self-Efficacy	.349	0.122	Established
Perceived Barrier <--> Cue to Action	-.001	0.000	Established
Perceived Barrier <--> Self-Efficacy	-.157	0.025	Established
Cue to Action <--> Self-Efficacy	.600	0.360	Established

Internal consistency was deemed to be acceptable if the Cronbach's alpha coefficients were more than 0.7. According to reliability analyses, Cronbach  $\alpha$  of the Perceived Susceptibility, Perceived Severity, Perceived Benefits, Perceived Barriers, Cues to Action, Self-Efficacy and Health Behavioural Intention were 0.83, 0.81, 0.86, 0.80, and 0.71, respectively in phase 1 and 0.87, 0.88, 0.86, 0.89, 0.84, 0.87 and 0.86, respectively in phase 2.

The detailed mean and standard deviation of each HBM component and Health Behavioural Intention to the socio-demographic characteristics are displayed in Table 5. The total mean score for each domain ranged from 14.03 to 21.32.

**Table 5: Result of the minimum and maximum scores, total mean score and SD in phase 2 (n=171)**

Constructs	N	Minimum	Maximum	Mean	SD
Perceived Susceptibility	171	5	25	14.03	4.04
Perceived Severity	171	5	25	16.81	4.44
Perceived Benefits	171	7	20	16.16	2.86
Perceived Barriers	171	6	30	21.32	4.99
Cue to Action	171	9	25	19.97	3.14
Self-Efficacy	171	9	25	18.04	3.87
Health Behavioural Intention	171	5	20	15.64	3.26

## **Discussion**

At the time when the study was conducted, there were no published papers based on HBM to evaluate cancer health perception among at-risk smokers. Geography, ethnicity, national, social, and genetic-related factors contribute to the disproportionate burden of cancer. Sarawak's population vulnerability to NPC is among the highest in the world. Although genetic predisposition may be the most important risk factor leading to higher incidence of NPC in Sarawak, individual behavioural variables are a key driver of community health that must not be underestimated [35].

A total of 34 items in the questionnaire were formulated consistent with the HBM and divided into two sections: HBM scale for smokers' perception of NPC; and health behavioural intention to smoking cessation. Both sections are constructed with a 5-point Likert scale ranging from "1 = strongly disagree" to "5 = strongly agree". The first section consists of 30 items and is arranged into six subcategories, each representing the six constructs of the health belief model – perceived susceptibility (5 items), perceived seriousness (5 items), perceived benefits (4 items), perceived barriers (6 items), cues to action (5 items), and self-efficacy (5 items). The second section includes 4 items that predict health behavioural intention (See Table S1 and S2).

Based on the validity and reliability tests, including face and content validity, construct validity, and internal consistency, the findings of the current study indicate that the questionnaire has promising psychometric properties. Ten experts advised on content validity, and 7 items that did not reach the threshold of CVR based on Lawshe's Table and were judged superfluous were removed [25]. Face validity was examined in a pilot study with 10 smokers who fulfilled the eligibility requirements to ensure cultural acceptance and assess relevance and readability within the local community. Given a satisfactory Impact Score of each item, no item was eliminated in the face validity stage. In the main study, at-risk smokers from various ethnic groups participated, which was conducted in urban, suburban and rural regions of Miri (the northern region of Sarawak). The KMO test yielded a result of 0.697 (Phase 1) and 0.830 (Phase 2) while the Bartlett's test of sphericity obtained 1746.76 (Phase 1) and 3362.86 (Phase 2), both with  $p$ -value  $< 0.001$ , indicating that the sample size was adequate and the correlation between the items was sufficient for factor analysis.

Construct validity primarily concerns with the degree to which a concept measures what it claims to measure [36]. Similar to a previous study [37], a number of analyses were conducted to assess the construct validity, including EFA, CFA, as well as convergent and discriminant validity. The EFA demonstrated in phase 1 that the seven-factor structure accounted for 63.01 percent of the overall variance. The cut-off point for factor loading was fixed at 0.30. According to EFA suggestion, HBI2 item (I am trying to quit smoking to prevent nose and throat cancer at this time) should be grouped together with Perceived Benefit since the factor loading (0.537) is higher than when it is grouped with Health Behavioural Intention (0.307). This item requires immediate smoking cessation, which may spark inconsistent answers as some respondents may not be prepared to quit. The Cronbach's  $\alpha$  coefficient value of 'Health Behavioural Intention' construct appeared to be satisfactory (Phase 1: 0.705; Phase 2: 0.861) and this item could potentially be essential on a larger scale. Thus, the researchers agreed not to delete this item.

In phase 2, CFA was performed to see if the seven-factor model derived by EFA could validate the association among the items based on the chosen framework. The loadings of all factors were more than 0.5. The goodness of fit was demonstrated to have an acceptable fit with the data, Chi Square = 641.705;  $df = 500$ ;  $P < 0.001$ ; CFI = 0.953; TLI: 0.948; RMSEA= 0.041 (90% CI 0.031 to 0.050). Following CFA, convergent and discriminant validity were tested in phase 2. The CR and AVE values for each component have to be higher than 0.7 and 0.5; respectively, which are fulfilled in the current study, suggesting an acceptable convergent validity [38]. Discriminant validity was evaluated between the

1  
2  
3 HBM constructs (excluding health behavioural intention construct). To establish acceptable  
4 discriminant validity, the factors' correlation coefficients with other factors must not be greater than  
5 each factor's AVE square root [34]. The current findings demonstrated established discriminant  
6 validity for all except for Perceived Benefit <--> Cue to Action. The explanation for this might be that  
7 the greater the perceived benefits of smoking cessation, the more likely smokers will look for cues to  
8 participate in such health-promoting behaviour, or vice versa. Future studies could delve deeper into  
9 the strength of the correlation, particularly between Perceived Benefit and Cue to Action. In terms of  
10 reliability, each construct for both phase 1 and 2 showed rationally acceptable Cronbach's  $\alpha$   
11 coefficient values as all of which were higher than 0.7, which demonstrates a high internal consistency  
12 [39].  
13  
14

15  
16 This study has several limitations. Firstly, it is a cross-sectional study using convenience sampling, and  
17 thus, it is susceptible to recall and selection bias. However, to mitigate recall bias, participants were  
18 given ample time to consider their responses before answering the questions. This study was carried  
19 out with the cooperation of smokers from accessible areas in Sarawak. However, due to the  
20 widespread locations, the population sizes were difficult to determine, which contributed to the  
21 second limitation. The third limitation was the relatively small sample size for both EFA (n=100) and  
22 CFA (n=171). However, Kline (1994) indicated that for EFA, a sample size of 100 is sufficient, while  
23 Anderson & Gerbing (1988) suggested that CFA/SEM may be reliably examined with a minimum  
24 sample size of 100–150 [40, 41].  
25  
26

27 This study provides practical implications. With it being valid and reliable, the public health officials  
28 and researchers now have a reason to launch a larger population-based study on health behavioural  
29 intention to minimize NPC. Given that the current smoking rates in Malaysia remain high, this  
30 questionnaire can help in understanding and determining the factors that influence smokers' health  
31 decisions. Subsequently, cancer risk can be reduced by better prediction, a comprehensive tobacco  
32 control programme, policy creation, and health interventions.  
33  
34

### 35 **Conclusions**

36  
37 In order to examine the variables affecting smoking cessation for cancer prevention, this study made  
38 an effort to develop a comprehensive HBM-based questionnaire. The results depict consistently  
39 satisfactory psychometric properties, confirming the validity and reliability. Considering that smoking  
40 is a major contributor to cancer, it is critical to address the health behavioural intention to uncover  
41 obstacles and implement improvements for a more successful intervention. The authors propose  
42 further studies to use the instruments for application in other smoking-related cancers in different  
43 susceptible populations and geographical locations.  
44  
45  
46  
47

### 48 **Funding**

49 Funding for the publication fee was received from RCSI & UCD Malaysia Campus.  
50  
51  
52  
53

### 54 **Conflicts of Interest**

55 The authors declare that there are no competing or potential conflicts of interest.  
56  
57  
58  
59

### 60 **Author Contributions**

1  
2  
3 Conceptualization: Kueh Martin, Fairuz Fadzilah Rahim, Abdul Rashid.

4  
5 Formal analysis: Kueh Martin, Fairuz Fadzilah Rahim.

6  
7 Investigation: Kueh Martin, Fairuz Fadzilah Rahim.

8  
9 Methodology: Kueh Martin, Fairuz Fadzilah Rahim.

10  
11 Project administration: Kueh Martin, Fairuz Fadzilah Rahim.

12  
13 Resources: Kueh Martin, Fairuz Fadzilah Rahim.

14  
15 Software: Kueh Martin.

16  
17 Supervision: Fairuz Fadzilah Rahim, Abdul Rashid.

18  
19 Validation: Kueh Martin.

20  
21 Visualization: Kueh Martin.

22  
23 Writing – original draft: Kueh Martin.

24  
25 Writing – review & editing: Kueh Martin, Fairuz Fadzilah Rahim, Abdul Rashid.

## 26 27 28 29 **Institutional Review Board Statement**

30  
31 The study was approved by Joint Penang Independent Ethics Committee on 13 August 2020 (Approval  
32 no. JPEC 20 0027).  
33

## 34 35 36 **Informed Consent Statement**

37  
38 Informed consent was obtained from all participants involved in the study.  
39

## 40 41 42 **Data Availability Statement**

43  
44 Extra data can be accessed via the Dryad data repository at <http://datadryad.org/> with the doi:  
45 <https://doi.org/10.5061/dryad.4tmpg4fbb>  
46  
47

## 48 49 **Acknowledgments**

50  
51 We express our gratitude to the hospital director in Miri and local estate managers for their helpful  
52 assistance and the participants of this study.  
53

54  
55 **Word count** 4236  
56

## 57 58 59 **References** 60


1. Institute for Health Metrics and Evaluation (IHME). Findings from the Global Burden of Disease Study 2017. In: IHME, editor. Seattle, WA. 2018. Available from: <http://www.healthdata.org/policy-report/findings-global-burden-disease-study-2017>
2. World Health Organization. WHO Report on Cancer: Setting priorities, investing wisely and providing care for all. 2020. Available from: <https://apps.who.int/iris/handle/10665/330745>
3. Wellmann KF. [Smoking and Health. On the Report of the Advisory Committee to the Surgeon General of the Public Health Service]. *Dtsch Med Wochenschr.* 1964, 89, 1085-6.
4. Hecht SS. Research opportunities related to establishing standards for tobacco products under the Family Smoking Prevention and Tobacco Control Act. *Nicotine & Tobacco Research.* 2011, 14(1), 18-28. <https://doi.org/10.1093/ntr/ntq216>
5. Viswanath K, Herbst RS, Land SR, Leischow SJ, Shields PG. Tobacco and Cancer: An American Association for Cancer Research Policy Statement. *Cancer Research.* 2010, 70(9), 3419-30. <https://doi.org/10.1158/0008-5472.can-10-1087>
6. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin.* 2021, 71(3), 209-49. <https://doi.org/10.3322/caac.21660>
7. Hashim D, Boffetta P, La Vecchia C, Rota M, Bertuccio P, Malvezzi M, et al. The global decrease in cancer mortality: trends and disparities. *Ann Oncol.* 2016, 27(5), 926-33. <https://doi.org/10.1093/annonc/mdw027>
8. Zavala VA, Bracci PM, Carethers JM, Carvajal-Carmona L, Coggins NB, Cruz-Correa MR, et al. Cancer health disparities in racial/ethnic minorities in the United States. *Br J Cancer.* 2021, 124(2), 315-32. <https://doi.org/10.1038/s41416-020-01038-6>
9. Lam KO, Lee AW, Choi CW, Sze HC, Zietman AL, Hopkins KI, et al. Global Pattern of Nasopharyngeal Cancer: Correlation of Outcome With Access to Radiation Therapy. *Int J Radiat Oncol Biol Phys.* 2016, 94(5), 1106-12. <https://doi.org/10.1016/j.ijrobp.2015.11.047>
10. Azizah A, Hashimah B, Nirmal K, Siti Zubaidah A, Puteri N, Nabihah A, et al. Malaysian National Cancer Registry Report 2012-2016 [Internet]. Malaysia: National Cancer Institute. . Putrajaya, Malaysia: National Cancer Institute, Ministry of Health, 2019. Available from: [https://www.moh.gov.my/moh/resources/Penerbitan/Laporan/Umum/2012-2016%20\(MNCRR\)/MNCRR\\_2012-2016\\_FINAL\\_\(PUBLISHED\\_2019\).pdf](https://www.moh.gov.my/moh/resources/Penerbitan/Laporan/Umum/2012-2016%20(MNCRR)/MNCRR_2012-2016_FINAL_(PUBLISHED_2019).pdf)
11. Devi BCR, Pisani P, Tang TS, Parkin DM. High Incidence of Nasopharyngeal Carcinoma in Native People of Sarawak, Borneo Island. *Cancer Epidemiology Biomarkers & Prevention.* 2004, 13(3), 482-6.
12. Tsao SW, Yip YL, Tsang CM, Pang PS, Lau VM, Zhang G, et al. Etiological factors of nasopharyngeal carcinoma. *Oral Oncol.* 2014, 50(5), 330-8. <https://doi.org/10.1016/j.oraloncology.2014.02.006>
13. Linton RE, Daker M, Khoo ASB, Choo DCY, Viljoen M, Neilsen PM. Nasopharyngeal carcinoma among the Bidayuh of Sarawak, Malaysia: history and risk factors (Review). *Oncol Lett.* 2021, 22(1), 514. <https://dx.doi.org/10.3892/ol.2021.12775>
14. Guo S-S, Huang P-Y, Chen Q-Y, Liu H, Tang L-Q, Zhang L, et al. The impact of smoking on the clinical outcome of locoregionally advanced nasopharyngeal carcinoma after chemoradiotherapy. *Radiation Oncology.* 2014, 9(1), 246. <https://doi.org/10.1186/s13014-014-0246-y>
15. Xue WQ, Qin HD, Ruan HL, Shugart YY, Jia WH. Quantitative association of tobacco smoking with the risk of nasopharyngeal carcinoma: a comprehensive meta-analysis of studies conducted between 1979 and 2011. *Am J Epidemiol.* 2013, 178(3), 325-38. <https://dx.doi.org/10.1093/aje/kws479>
16. Institute for Public Health. National Health and Morbidity Survey 2015 (NHMS 2015). Ministry of Health Malaysia Kuala Lumpur; 2015. Available from: <https://www.moh.gov.my/moh/resources/nhmsreport2015vol2.pdf>

17. Rahman M, Arif M, Razak MFA, Suhaili M, Tambi Z, Akoi C, et al. Factors associated with tobacco use among the adult population in Sarawak, Malaysia: A cross sectional study. *Epidemiology Biostatistics and Public Health*. 2015, 12, 1-9. <https://doi.org/10.2427/10292>
18. Champion VL, Skinner CS. The health belief model. *Health behavior and health education: Theory, research, and practice*, 4th ed. San Francisco, CA, US: Jossey-Bass, 2008. p. 45-65.
19. Maiman LA, Becker MH. The Health Belief Model: Origins and Correlates in Psychological Theory. *Health Education Monographs*. 1974, 2(4), 336-53. <https://doi.org/10.1177/109019817400200404>
20. Odedina FT, Dagne G, Pressey S, Odedina O, Emanuel F, Scrivens J, et al. Prostate cancer health and cultural beliefs of black men: The Florida Prostate Cancer Disparity Project. *Infectious Agents and Cancer*. 2011, 6(2), S10. <https://dx.doi.org/10.1186%2F1750-9378-6-S2-S10>
21. Solomon K, Tamire M, Kaba M. Predictors of cervical cancer screening practice among HIV positive women attending adult anti-retroviral treatment clinics in Bishoftu town, Ethiopia: the application of a health belief model. *BMC Cancer*. 2019, 19(1), 989. <https://doi.org/10.1186/s12885-019-6171-6>
22. Tavafian SS, Hasani L, Aghamolaei T, Zare S, Gregory D. Prediction of breast self-examination in a sample of Iranian women: an application of the Health Belief Model. *BMC Women's Health*. 2009, 9(1), 37. <https://doi.org/10.1186/1472-6874-9-37>
23. LaMorte., Wayne. W. The Health Belief Model: Behavioral Change Models 2019. Available from: <http://sphweb.bumc.bu.edu/otlt/MPH-Modules/SB/BehavioralChangeTheories/BehavioralChangeTheories2.html>
24. Beaton DE, Bombardier C, Guillemin F, Ferraz MB. Guidelines for the process of cross-cultural adaptation of self-report measures. *Spine*. 2000, 25(24), 3186-91. <https://doi.org/10.1097/00007632-200012150-00014>
25. Lawshe CH. A quantitative approach to content validity. *Personnel psychology*. 1975, 28(4), 563-75. <https://doi.org/10.1111/j.1744-6570.1975.tb01393.x>
26. Samet JM, Wipfli H, Platz EA, Bhavsar N. A Dictionary of Epidemiology, Fifth Edition: Edited by Miquel Porta. *American Journal of Epidemiology*. 2009, 170(11), 1449-51. <https://doi.org/10.1093/aje/kwp322>
27. Boateng, G. O., Neilands, T. B., Frongillo, E. A., Melgar-Quiñonez, H. R., & Young, S. L. (2018). Best Practices for Developing and Validating Scales for Health, Social, and Behavioral Research: A Primer. *Frontiers in public health*, 6, 149. <https://doi.org/10.3389/fpubh.2018.00149>
28. Lacasse Y, Godbout C, Sériès F. Health-related quality of life in obstructive sleep apnoea. *Eur Respir J*. 2002, 19(3), 499-503. <https://doi.org/10.1183/09031936.02.00216902>
29. Suhr DD. Exploratory or confirmatory factor analysis? 2006. Available from: <https://support.sas.com/resources/papers/proceedings/proceedings/sugi31/200-31.pdf>
30. [dataset] Kueh M, Rahim FF, Rashid A. Data from: Development and validation of the health behavioural intention on smoking cessation to prevent nasopharyngeal cancer in Sarawak, Malaysia based on the Health Belief Model: a cross-sectional study. Dryad Digital Repository, November 18, 2021. <https://doi.org/10.5061/dryad.4tmpg4fbb>
31. Munro BH. *Statistical methods for health care research: lippincott williams & wilkins*; 2005.
32. Xiang B, Wong HM, Cao W, Perfecto AP, McGrath CPJ. Development and validation of the Oral health behavior questionnaire for adolescents based on the health belief model (OHBQAIBM). *BMC Public Health*. 2020, 20(1), 701. <https://doi.org/10.1186/s12889-020-08851-x>
33. Brown TA. *Confirmatory factor analysis for applied research*. New York, NY, US: The Guilford Press; 2006.
34. Fornell C, Larcker DF. Evaluating structural equation models with unobservable variables and measurement error. *Journal of marketing research*. 1981, 18(1), 39-50. <https://doi.org/10.2307/3151312>
35. McGinnis JM, Williams-Russo P, Knickman JR. The case for more active policy attention to health promotion. *Health affairs*. 2002, 21(2), 78-93. <https://doi.org/10.1377/hlthaff.21.2.78>



- 1  
2  
3 36. Cohen RJ, Swerdlik ME, Phillips SM. Psychological testing and assessment: An introduction to  
4 tests and measurement: Mayfield Publishing Co; 1996.
- 5 37. Shamsalinia A, Moradi M, Farahani MA, Masoudi R, Ghadimi R, Rad RE, et al. Designing and  
6 psychometric evaluation of disease-related fear scale (D-RFS) in adults with epilepsy: A sequential  
7 exploratory mixed methods design. *Epilepsy & Behavior*. 2020, 110, 107169.  
8 <https://doi.org/10.1016/j.yebeh.2020.107169>
- 9 38. Schreiber JB, Nora A, Stage FK, Barlow EA, King J. Reporting structural equation modeling  
10 and confirmatory factor analysis results: A review. *The Journal of educational research*. 2006, 99(6),  
11 323-38. <https://doi.org/10.3200/JOER.99.6.323-338>
- 12 39. Kline P. *The handbook of psychological testing*: Psychology Press, 2000.  
13 <https://doi.org/10.4324/9781315812274>
- 14 40. Kline P. *An Easy Guide to Factor Analysis* (1st ed.). 1st edition ed. London. 1994, p. 208.  
15 <https://doi.org/10.4324/9781315788135>
- 16 41. Anderson JC, Gerbing DW. Structural Equation Modeling in Practice: A Review and  
17 Recommended Two-Step Approach. *Psychological Bulletin*. 1988, 103, 411-423.  
18 <http://dx.doi.org/10.1037/0033-2909.103.3.411>
- 19  
20  
21  
22  
23  
24

25 **Figure 1. Flow diagram of the development and validation of the Health Belief Model**  
26 **questionnaire to promote smoking cessation for nasopharyngeal cancer prevention.**  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**Figure 1. Flow diagram of the development and validation of the Health Belief Model questionnaire to promote smoking cessation for nasopharyngeal cancer prevention.**

Table S1: Questionnaire to promote smoking cessation for nasopharyngeal cancer prevention (English version).

### Section 1: Perceptions towards nose and throat cancer

Please choose the best answer options to indicate your level of agreement.

Constructs of Health Belief Model	Questions	Strongly disagree	Disagree	Neutral	Agree	Strongly agree
Perceived susceptibility	1. I feel that I will get nose and throat cancer in the future.					
	2. My chances of getting nose and throat cancer are high.					
	3. I cannot avoid myself from getting nose and throat cancer.					
	4. I am worried about getting nose and throat cancer due to family history.					
	5. My smoking habit makes me more likely than average to get nose and throat cancer.					
Perceived seriousness	6. The thought of nose and throat cancer scares me.					
	7. If I had nose and throat cancer, the cost of treatment can be a financial strain.					
	8. Nose and throat cancer would threaten a relationship with my family.					

	9. If I had nose and throat cancer my whole life would change.					
	10. If I developed nose and throat cancer, I would not live long.					
Perceived benefits	11. Quit smoking decreases my chance of getting nose and throat cancer.					
	12. Quit smoking decreases my chance of dying from nose and throat cancer.					
	13. Quit smoking can improve my health.					
	14. I feel less anxious about nose and throat cancer if I quit smoking.					
Perceived barriers	15. It is difficult to quit tobacco smoking (e.g., peer pressure).					
	16. I feel anxious without smoking.					
	17. Tobacco smoking relieves my stress.					
	18. I experience headache without smoking.					
	19. I experience excessive salivation without smoking.					
	20. I think getting nose and throat cancer is destiny and quitting smoking will not change it.					
Cues to action	21. I will quit smoking if I have social support.					

	22. I will quit smoking if there are information sources that reminds me. (Examples of sources include: the internet, newspapers, radio and TV).					
	23. I will quit smoking if I have the will to change.					
	24. I will quit smoking if I know the diseases related to smoking.					
	25. I will quit smoking if there are health professionals to assist me.					
Self-efficacy	26. I can refuse to smoke when I am thinking about difficult problem.					
	27. I can refuse the urge to smoke.					
	28. I can refuse to smoke when I see someone else smoking.					
	29. I can refuse to smoke when offered by my friends/ family.					
	30. I can refuse from buying cigarettes when I have extra pocket money.					

**Section 2: Health Behavioural Intention on smoking cessation**

Please choose the best answer options to indicate your level of agreement.

Statements	Strongly disagree	Disagree	Neutral	Agree	Strongly agree
------------	-------------------	----------	---------	-------	----------------

1					
2					
3					
4	1. I would like to lead a healthier lifestyle to prevent nose and throat cancer.				
5					
6					
7	2. I am trying to quit smoking to prevent nose and throat cancer at this time.				
8					
9					
10					
11	3. I plan to quit smoking to prevent nose and throat cancer within six months.				
12					
13					
14	4. I would like to quit smoking to prevent nose and throat cancer but have never really tried.				
15					
16					
17					
18					
19					
20					
21					
22					
23					
24					
25					
26					
27					
28					
29					
30					
31					
32					
33					
34					
35					
36					
37					
38					
39					
40					
41					
42					
43					
44					
45					
46					
47					
48					
49					
50					
51					
52					
53					
54					
55					
56					
57					
58					
59					
60					

For peer review only

Table S2: Questionnaire to promote smoking cessation for nasopharyngeal cancer prevention (Malay version- *Borang kajiselidik untuk menggalakkan niat tingkah laku kesihatan berkenaan berhenti merokok bagi pencegahan kanser pangkal hidung*)

**Bahagian 1: Persepsi terhadap kanser hidung dan tekak.**

Sila tandakan pilihan jawapan terbaik untuk menunjukkan tahap persetujuan anda.

Domain Model Kepercayaan Kesihatan	Soalan	Sangat tidak setuju	Tidak setuju	Kurang bersetuju	Setuju	Sangat setuju
Kepercayaan kepada tiada daya tahan	1. Saya merasakan bahawa saya akan mendapat kanser pangkal hidung pada masa akan datang.					
	2. Peluang saya mendapat kanser pangkal hidung adalah tinggi.					
	3. Saya tidak dapat mengelakkan diri daripada mendapat kanser pangkal hidung.					
	4. Saya bimbang terkena kanser pangkal hidung kerana ahli keluarga saya menghadapi masalah ini.					
	5. Tabiat merokok saya menyebabkan saya lebih berisiko menghidap kanser pangkal hidung.					
Kepercayaan kepada bahaya	6. Risiko dan kesan-kesan kanser pangkal hidung menakutkan saya.					
	7. Jika saya mempunyai kanser pangkal hidung, kos					

	rawatan akan menjadi beban kewangan keluarga saya.					
	8. Kanser pangkal hidung akan merosakkan hubungan antara ahli keluarga saya.					
	9. Jika saya mempunyai kanser pangkal hidung, kehidupan saya akan berubah.					
	10. Jika saya mempunyai kanser pangkal hidung, saya tidak akan hidup lama.					
Kepercayaan kepada manfaat	11. Berhenti merokok akan mengurangkan peluang saya mendapat kanser pangkal hidung.					
	12. Berhenti merokok akan mengurangkan risiko kematian disebabkan kanser pangkal hidung.					
	13. Berhenti merokok amat penting untuk meningkatkan kesihatan saya.					
	14. Berhenti merokok akan mengurangkan kerisauan saya terhadap kanser pangkal hidung.					
Kepercayaan kepada halangan	15. Saya berasa sukar untuk menghentikan tabiat merokok atas					



	sebab tekanan rakan sebaya dan lain-lain.					
	16. Saya akan berasa bimbang akan sesuatu tanpa merokok.					
	17. Merokok menghilangkan tekanan saya.					
	18. Jika saya tidak merokok, saya akan mengalami sakit kepala.					
	19. Jika saya tidak merokok, saya akan mengalami air liur berlebihan.					
	20. Saya rasa mendapat kanser pangkal hidung adalah takdir dan berhenti merokok tidak akan mengubahnya.					
Isyarat untuk bertindak	21. Jika saya mempunyai sokongan sosial, saya akan berhenti merokok.					
	22. Jika beberapa sumber maklumat mengingatkan saya, saya akan berhenti merokok. (Contoh sumber maklumat termasuk: internet, surat khabar, radio dan TV).					
	23. Saya akan berhenti merokok sekiranya saya mempunyai kemahuan untuk berubah.					

	24. Menyedari bahaya merokok akan membantu saya berhenti merokok.					
	25. Saya akan berhenti merokok sekiranya ahli profesional kesihatan membantu saya.					
Keberkesanan diri	26. Saya boleh menolak merokok apabila saya ingin memikirkan masalah yang sukar.					
	27. Saya boleh menolak merokok apabila saya mempunyai keinginan untuk merokok.					
	28. Saya boleh menolak merokok apabila saya melihat orang lain merokok.					
	29. Saya boleh menolak merokok apabila kawan/ keluarga saya mengajak saya untuk merokok.					
	30. Saya boleh menolak membeli rokok apabila saya mempunyai lebihan wang saku.					

## Bahagian 2: Tingkah laku untuk berhenti merokok demi kesihatan

Sila tandakan pilihan jawapan terbaik untuk menunjukkan tahap persetujuan anda.

Soalan	Sangat tidak bersetuju	Tidak setuju	Kurang bersetuju	Setuju	Sangat setuju
--------	------------------------	--------------	------------------	--------	---------------

1. Saya akan menjalani gaya hidup yang lebih sehat untuk mencegah kanker pangkal hidung.					
2. Saya sedang berusaha untuk berhenti merokok untuk mengurangi risiko kanker pangkal hidung pada masa ini.					
3. Saya merancang untuk berhenti merokok untuk mengurangi risiko kanker pangkal hidung dalam masa enam bulan.					
4. Saya ingin berhenti merokok untuk mengurangi risiko kanker pangkal hidung tetapi tidak pernah mencuba.					

# Reporting checklist for cross sectional study.

Based on the STROBE cross sectional guidelines.

## Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the STROBE cross sectional reporting guidelines, and cite them as:

von Elm E, Altman DG, Egger M, Pocock SJ, Gotsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.

	Reporting Item	Page Number
	<b>Title and abstract</b>	
	Title <a href="#">#1a</a> Indicate the study's design with a commonly used term in the title or the abstract	3

1	Abstract	<a href="#">#1b</a>	Provide in the abstract an	3
2				
3			informative and balanced summary	
4				
5			of what was done and what was	
6				
7			found	
8				
9				
10				
11	<b>Introduction</b>			
12				
13				
14	Background /	<a href="#">#2</a>	Explain the scientific background	4-5
15				
16	rationale		and rationale for the investigation	
17				
18			being reported	
19				
20				
21	Objectives	<a href="#">#3</a>	State specific objectives, including	5
22				
23			any prespecified hypotheses	
24				
25				
26				
27	<b>Methods</b>			
28				
29				
30	Study design	<a href="#">#4</a>	Present key elements of study	6-7
31				
32			design early in the paper	
33				
34				
35				
36	Setting	<a href="#">#5</a>	Describe the setting, locations, and	7
37				
38			relevant dates, including periods of	
39				
40			recruitment, exposure, follow-up,	
41				
42			and data collection	
43				
44				
45	Eligibility criteria	<a href="#">#6a</a>	Give the eligibility criteria, and the	7
46				
47			sources and methods of selection of	
48				
49			participants.	
50				
51				
52				
53		<a href="#">#7</a>	Clearly define all outcomes,	7
54				
55			exposures, predictors, potential	
56				
57				
58				
59				
60				

1		confounders, and effect modifiers.	
2			
3		Give diagnostic criteria, if applicable	
4			
5			
6	Data sources /	<a href="#">#8</a> For each variable of interest give	8-9
7			
8	measurement	sources of data and details of	
9			
10		methods of assessment	
11			
12		(measurement). Describe	
13			
14		comparability of assessment	
15			
16		methods if there is more than one	
17			
18		group. Give information separately	
19			
20		for for exposed and unexposed	
21			
22		groups if applicable.	
23			
24			
25			
26			
27	Bias	<a href="#">#9</a> Describe any efforts to address	15. We involved experts and
28			
29		potential sources of bias	participants of different
30			
31			background and ethnic groups in
32			
33			hopes to reduce biasness. We are
34			
35			cognizant that convenience
36			
37			sampling was approached, which
38			
39			gives rise to selection and recall
40			
41			bias. We highlighted as the first
42			
43			limitation in the manuscript.
44			
45			
46			
47			
48	Study size	<a href="#">#10</a> Explain how the study size was	15
49			
50		arrived at	
51			
52			
53	Quantitative	<a href="#">#11</a> Explain how quantitative variables	7-8
54			
55	variables	were handled in the analyses. If	
56			
57			
58			
59			
60			

1		applicable, describe which	
2			
3		groupings were chosen, and why	
4			
5			
6	Statistical	<a href="#">#12a</a> Describe all statistical methods,	8-9
7			
8	methods	including those used to control for	
9			
10		confounding	
11			
12			
13	Statistical	<a href="#">#12b</a> Describe any methods used to	8-9
14			
15	methods	examine subgroups and interactions	
16			
17			
18			
19	Statistical	<a href="#">#12c</a> Explain how missing data were	9
20			
21	methods	addressed	
22			
23			
24	Statistical	<a href="#">#12d</a> If applicable, describe analytical	9
25			
26	methods	methods taking account of sampling	
27			
28		strategy	
29			
30			
31			
32	Statistical	<a href="#">#12e</a> Describe any sensitivity analyses	N/A
33			
34	methods		
35			
36			
37	<b>Results</b>		
38			
39			
40	Participants	<a href="#">#13a</a> Report numbers of individuals at	N/A. Do not have a list of numbers
41			
42		each stage of study—eg numbers	potentially eligible.
43			
44		potentially eligible, examined for	
45			
46		eligibility, confirmed eligible,	
47			
48		included in the study, completing	
49			
50		follow-up, and analysed. Give	
51			
52		information separately for for	
53			
54			
55			
56			
57			
58			
59			
60			

1		exposed and unexposed groups if	
2		applicable.	
3			
4			
5			
6	Participants	<a href="#">#13b</a> Give reasons for non-participation at	N/A
7			
8		each stage	
9			
10			
11	Participants	<a href="#">#13c</a> Consider use of a flow diagram	8
12			
13			
14	Descriptive data	<a href="#">#14a</a> Give characteristics of study	9-10
15		participants (eg demographic,	
16		clinical, social) and information on	
17		exposures and potential	
18		confounders. Give information	
19		separately for exposed and	
20		unexposed groups if applicable.	
21			
22			
23			
24			
25			
26			
27			
28			
29			
30			
31	Descriptive data	<a href="#">#14b</a> Indicate number of participants with	N/A. No missing data was
32		missing data for each variable of	collected
33		interest	
34			
35			
36			
37			
38			
39	Outcome data	<a href="#">#15</a> Report numbers of outcome events	N/A. This study focuses on
40		or summary measures. Give	validating the questionnaire with a
41		information separately for exposed	series of analysis.
42		and unexposed groups if applicable.	
43			
44			
45			
46			
47			
48			
49	Main results	<a href="#">#16a</a> Give unadjusted estimates and, if	N/A. This study focuses on
50		applicable, confounder-adjusted	validating the questionnaire with a
51		estimates and their precision (eg,	series of analysis.
52		95% confidence interval). Make	
53		clear which confounders were	
54			
55			
56			
57			
58			
59			
60			



1		adjusted for and why they were	
2		included	
3			
4			
5			
6	Main results	<a href="#">#16b</a> Report category boundaries when	N/A. This study focuses on
7			
8		continuous variables were	validating the questionnaire with a
9			
10		categorized	series of analysis.
11			
12			
13	Main results	<a href="#">#16c</a> If relevant, consider translating	N/A. This study focuses on
14			
15		estimates of relative risk into	validating the questionnaire with a
16			
17		absolute risk for a meaningful time	series of analysis.
18			
19		period	
20			
21			
22			
23	Other analyses	<a href="#">#17</a> Report other analyses done—e.g.,	9-13
24			
25		analyses of subgroups and	
26			
27		interactions, and sensitivity analyses	
28			
29			
30			
31	<b>Discussion</b>		
32			
33			
34	Key results	<a href="#">#18</a> Summarise key results with	14-15
35			
36		reference to study objectives	
37			
38			
39	Limitations	<a href="#">#19</a> Discuss limitations of the study,	15
40			
41		taking into account sources of	
42			
43		potential bias or imprecision.	
44			
45		Discuss both direction and	
46			
47		magnitude of any potential bias.	
48			
49			
50			
51	Interpretation	<a href="#">#20</a> Give a cautious overall interpretation	14
52			
53		considering objectives, limitations,	
54			
55		multiplicity of analyses, results from	
56			
57			
58			
59			
60			

1 similar studies, and other relevant  
2  
3 evidence.

4  
5  
6 Generalisability [#21](#) Discuss the generalisability (external 14-15  
7  
8 validity) of the study results  
9

10  
11 **Other**

12  
13 **Information**

14  
15  
16 Funding [#22](#) Give the source of funding and the 15  
17  
18 role of the funders for the present  
19  
20 study and, if applicable, for the  
21  
22 original study on which the present  
23  
24 article is based  
25  
26

27  
28  
29 **Notes:**

- 30  
31
- 32 • 9: p. 15: We involved experts and participants of different background and ethnic groups in  
33 hopes to reduce biasness. We are cognizant that convenience sampling was approached, which  
34 gives rise to selection and recall bias. We highlighted as the first limitation in the manuscript.  
35  
36
  - 37 • 13a: N/A. Do not have a list of numbers potentially eligible.  
38
  - 39 • 14b: N/A. No missing data was collected  
40  
41
  - 42 • 15: N/A. This study focuses on validating the questionnaire with a series of analysis.  
43  
44
  - 45 • 16a: N/A. This study focuses on validating the questionnaire with a series of analysis.  
46  
47
  - 48 • 16b: N/A. This study focuses on validating the questionnaire with a series of analysis.  
49  
50
  - 51 • 16c: N/A. This study focuses on validating the questionnaire with a series of analysis. The  
52 STROBE checklist is distributed under the terms of the Creative Commons Attribution License  
53  
54  
55  
56  
57  
58  
59

1 CC-BY. This checklist was completed on 19. September 2021 using

2 <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with

3 [Penelope.ai](#)

4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only